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Introduction
Chapter 1 starts with discussing mutations on the BRCA1/2 genes in relation to the 
development of breast and ovarian cancer, followed by a discussion of the genetic 
counseling process relevant to women with a suspected genetic predisposition. Next, the 
risk management options available to women with an elevated risk of breast and ovarian 
cancer are studied. Then, an overview of currently known and possible predictors of the 
uptake of risk management options is given. Lastly, current interventions to alleviate 
sequelae following risk-reducing salpingo-oophorectomy (RRSO) are summarized and 
opportunities for future research are described. Chapter 1 concludes with an outline of 
this thesis.
Breast and ovarian cancer and genetic susceptibility
Pathogenic mutations in the BRCA1 or BRCA2 gene have been found to account for the 
majority of hereditary breast and ovarian cancer cases1–3. BRCA1 and BRCA2 genes are 
tumor suppressor genes that have a function in ensuring genomic integrity by its roles in 
the DNA double-strand break repair process4. Pathogenic mutations in these genes can 
interfere with their role in this DNA repair process1,2,4. The discovery of these genes in 1994 
and 1995 has made genetic testing and the assessment of the risk of breast or ovarian 
cancer in individual women and their relatives possible1,2. The inheritance pattern of a 
BRCA1/2 mutation is autosomal dominant. It is estimated that approximately 7% of all 
breast cancer cases and 10% of all ovarian cancer cases are in women with a BRCA1 or 
BRCA2 gene mutation5,6.
BRCA1/2 associated breast cancer risk
In a recent large prospective cohort study it was estimated that women who carry a BRCA1 
or BRCA2 mutation have a cumulative breast cancer risk to the age of 80 years of 72% 
(95% confidence interval (CI), 65%-79%) and 69% (95%CI, 61%-77%), respectively7. Breast 
cancer incidence starts to rise between the ages of 21 and 30 years in both BRCA1 and 
BRCA2 mutation carriers. Peak incidence is reached between 41 and 50 years of age in 
BRCA1 mutation carriers and between 51 and 60 years of age in BRCA2 mutation carriers7.
BRCA1/2 associated ovarian cancer risk
In the same cohort study it was estimated that BRCA1 and BRCA2 mutation carriers have 
a cumulative ovarian cancer risk at the age 80 years of 44% (95% CI, 36%-53%) and 17% 
(95% CI, 11%-25%), respectively7. Ovarian cancer incidence starts to rise between the 
ages of 41 and 50 years in BRCA1 mutation carriers and between the ages of 51 and 60 
years in BRCA2 mutation carriers7. In the Northern Netherlands an even earlier rise has 
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been observed in BRCA1 mutation carriers, starting in their late thirties8. Peak incidence 
is reached between 61 and 70 years of age in both BRCA1 and BRCA2 mutation carriers7. 
Table 1: Indications for referral to a clinical geneticist for women according to the most 
recent Dutch guidelines for breast cancer9,10 and hereditary and familial ovarian cancer9,10. 
For women with ovarian/fallopian tube cancer
•    Woman with ovarian/fallopian tube cancer, regardless of family history, age at diagnosis and histological 
type 
For women with breast cancer
•    Woman with breast cancer and first or second degree relatives with ovarian/fallopian tube cancer, regardless 
of age at diagnosis 
•   Woman with breast cancer and a relative with BRCA1/2 mutation 
•   Woman with breast cancer < 40 years 
•   Woman with bilateral breast cancer with first case < 50 years
•   Woman with ≥ 2 primary breast cancer cases in ipsilateral breast, first case < 50 years 
•   Woman with triple negative breast cancer < 60 years 
•   Woman with breast cancer < 50 years and ≥ 1 first degree relatives with breast cancer < 50 years 
•   Woman with breast cancer < 50 years and first degree relative with prostate cancer < 60 years 
•    Woman with breast cancer and ≥ 2 first and second degree relatives with breast cancer, at least 1 case < 50 
years, all on the same side of the family 
For women without ovarian/fallopian tube cancer or breast cancer*
•   First degree relative with ovarian or fallopian tube cancer, regardless of age at diagnosis
•   First or second degree relative with BRCA1/2 mutation
•   First degree female relative with breast cancer < 40 years 
•   First degree female relative with bilateral breast cancer, first case < 50 years 
•    First degree female relative with ≥ 2 primary breast cancer cases in ipsilateral breast, 
first case < 50 years 
•   First degree female relative with triple negative breast cancer < 60 years 
•   First degree male relative with breast cancer 
•    First degree female relative with breast cancer < 50 years and a first degree relative with prostate cancer < 
60 years, both on same side of family. 
•   ≥ 2 first degree relatives with breast cancer < 50 years
•    ≥ 3 first and second degree relatives with breast cancer, at least 1 case < 50 years, all on the same side of 
the family 
        * there is a strong preference to refer the affected family member for clinical genetic assessment because DNA testing will start with this person. 
Advice for the family members of the affected person will follow based on the DNA testing and family history.
Genetic counseling and risk-management options for hereditary breast and 
ovarian cancer 
When breast and/or ovarian cancer cluster in a family, affected members of this family 
should be referred to the clinical geneticist to investigate if they carry a BRCA1/2 mutation. 
As specified in the Dutch national guidelines, every women with ovarian cancer should 
be offered genetic testing, regardless of age at diagnosis, histological type of cancer and 
family history9. The most up-to-date indications for referral have been specified in the 
recent update of the current national guideline on breast cancer and the national guideline 
for hereditary and familial ovarian cancer (Table 1)9,10. Based on a detailed medical history 
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of breast and ovarian cancer and family history of breast, ovarian and prostate cancer, 
the clinical geneticist assesses whether gene panel testing including (but not limited to) 
BRCA1 and BRCA2 genes is indicated. If an indication is present, women receive extensive 
counseling on the personal and familial implications of DNA testing11. 
Risk-management options
Several risk-management options exist in case a woman is proven to be a BRCA1/2 
mutation carrier. Regarding breast cancer risk, BRCA1/2 mutation carriers can either opt 
for breast cancer screening or for risk-reducing mastectomy (RRM) with or without breast 
reconstruction12. With respect to ovarian cancer, risk-reducing salpingo-oophorectomy 
(RRSO) is currently the only proven option to effectively reduce the risk of dying of 
ovarian cancer, because screening was found to be ineffective for early detection of 
ovarian cancer13–15. In the Netherlands, women are extensively counseled on the optimal 
timing, effectiveness and consequences of breast and ovarian cancer risk management 
options by a multidisciplinary team consisting of clinical geneticists, surgical oncologists, 
gynecological oncologists, oncology nurses, psychologists, plastic surgeons and 
radiologists11,16.
Effectiveness of breast cancer screening & RRM
BRCA1/2 mutation carriers can opt for an intensive breast cancer screening program. The 
screening recommendations have been specified in current national guidelines10. For 
BRCA1 mutation carriers this starts at the age of 25 years with annual MRI and from the age 
of 40 years adding mammography once every two years. The intensive screening program 
for BRCA2 mutation carriers starts at the age of 25 years with annual MRI and from the 
age of 30 years adding annual mammography. From the age of 60 to 75 years, BRCA1 
and BRCA2 mutation carriers are screened annually with mammography only, unless the 
breast tissue is heterogeneous or extremely dense, in which case alternating annual MRI 
and mammography is advised. The evidence on the benefit of clinical breast examination 
in addition to imaging is limited. There is a study showing that the addition of clinical 
breast examination to mammography increased breast cancer detection17. However, in 
another study in women screened using MRI, the benefit of clinical breast examination 
was found to be minimal or none at all18.
The alternative, RRM, is offered as an option to women from the age of 25 years and after 
comprehensive counseling on the arguments for and against12. A recent review reported 
that the breast cancer risk reduction by RRM ranges from 90% to 100%19. Model-based 
analyses suggest that RRM at the age of 25 years combined with RRSO at the age of 40 
years results in only slightly better survival compared to intensive breast cancer screening 
due to the already high survival in the breast cancer screening programme20. However, 
empirical evidence on the comparative effectiveness on survival of intensive screening 
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versus RRM is lacking and a definite answer on this question remains unknown. As will 
be discussed in the next paragraph, survival is not the only important factor to take 
into account in decision making, because from the patients’ perspective, having to face 
burdensome cancer treatments or having to deal with the stress of false positive screening 
results are highly relevant as well. 
Consequences of breast cancer screening & RRM
The choice between RRM and intensive breast cancer screening is complex because it 
is not only based on the comparative effectiveness of both options in terms of cancer 
prevention, but also a matter of weighing the other consequences either options have 
for these women. For example, as all screening tests have a specificity of less than 100%, 
women who choose breast cancer screening can be faced with false positive results, 
anxiety and subsequent additional investigation. Studies have found that women who are 
given an all-clear result and are placed on the routine recall do not experience high levels 
of anxiety due to screening21,22. However, women who do need additional investigation 
experience a temporary increase in anxiety levels21–25. 
In case of RRM, women can experience a decrease in general and cancer-related 
anxiety26–28. However, in several studies women report a decline in sexual functioning and 
a persistently lower body image after RRM with or without reconstruction when compared 
to before the procedure26–30. Women who opted for RRM with breast reconstruction did 
report higher levels of satisfaction with body shape and appearance than women who 
did not.30. However, after breast reconstruction following RRM, women can be faced with 
a lack of sensation in the reconstructed breasts and surgical complications during the 
reconstruction process29,31,32.
Effectiveness of RRSO
RRSO is recommended at an age, before the incidence of ovarian cancer starts rising, i.e. 
between 35 and 40 years of age for BRCA1 mutation carriers and between 40 and 45 years 
of age for BRCA2 mutation carriers, provided that childbearing has been completed9,33–36. 
When performed within the recommended age range, RRSO reduces the risk of ovarian 
cancer up to 96%37–40. In earlier studies RRSO was also associated with approximately a 50% 
reduction of breast cancer risk in BRCA1/2 mutation carriers, however more recent studies 
suggest that this protective effect is much less pronounced than previously thought40,41.
Consequences of RRSO
What makes the uptake and timing of RRSO complex for BRCA1/2 mutation carriers is 
that these women are often young, at premenopausal age and that RRSO induces acute 
surgical menopause. Frequently mentioned menopausal symptoms after RRSO are hot 
flushes, night sweats, loss of sexual desire and vaginal dryness32,42,51–53,43–50. Menopausal 
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symptoms occur not only earlier, but also more severely after acute surgical menopause 
in comparison to natural menopause54,55. Furthermore, these symptoms can persist many 
years after RRSO43. Regarding sexual difficulties after RRSO, the prevalence of sexual 
dysfunction and hypoactive sexual desire disorder has been found to be 74% (95% CI: 66–
81%) and 73% (95% CI: 64–80%), respectively. The most commonly experienced sexual 
symptoms after surgical menopause are: reduced libido, vaginal dryness, pain during 
intercourse, reduced sexual satisfaction and reduced ability to achieve an orgasm53,56. 
Women who experience a high level of relationship satisfaction more often continue 
to have regular sexual activity, even when facing vaginal menopausal symptoms53,57. 
Hormone replacement therapy (HRT) reduces vasomotor and sexual symptoms after 
RRSO, however not to the premenopausal situation58.
In conclusion, although RRM and RRSO are very effective procedures to reduce the risk of 
breast and ovarian cancer, they have a profound impact on quality of life of the women 
involved. This thesis focusses on factors associated with the decision for preventive surgery 
in BRCA1 and BRCA2 mutation carriers (Part I) and on possible psychological interventions 
to mitigate the menopausal and sexual side effects after RRSO (Part II).
Part I:  
Factors associated with the uptake of risk-reducing surgery 
The decision whether or not to choose risk-reducing surgery (i.e. RRM and/or RRSO) is a 
complex process. Possible factors that may influence the decision process are personal 
or family history of cancer (e.g. having first degree relatives with breast/ovarian cancer), 
demographic characteristics (e.g. age, parity), psychological factors (e.g. perceived risk, 
cancer worry, cancer anxiety, effectiveness) and actual cancer risk7,59,68–77,60–67. Optimal 
decisional support integrates all these factors to ensure individualized and medically 
adequate decisions and optimal support of patients in terms of psychological well-being 
and decisional satisfaction. In order to address all relevant factors during counseling and 
provide adequate support it is important to further identify which factors influence the 
decision to undergo risk-reducing surgery. 
Socio-demographic characteristics, family history and personal history of cancer are 
the most commonly studied factors. Several studies have reported that a higher level of 
education, being married, having children, a personal history of breast cancer, unilateral 
therapeutic mastectomy and having relatives with breast and/or ovarian cancer were 
associated with the decision for RRM59–68. Likewise, having children, a higher level of 
education, a personal history of breast cancer, a family history of breast and/or ovarian 
cancer have been reported to be associated with the decision to undergo RRSO65,69–73.
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As described above, risk-reducing surgeries can best be performed before a certain age for 
optimal effectiveness and from a certain age in order to prevent side effects at too young 
an age. This is especially true for RRSO which is advised before the age the incidence of 
ovarian cancer starts to rise until a few years thereafter, as there are no effective screening 
alternatives and ovarian cancer has a high mortality rate7,78. Therefore, factors that 
influence the timing of risk-reducing surgery after DNA test results disclosure also need to 
be understood. These factors help understand what constitutes the “right time” to choose 
risk-reducing surgery for women74,75. This understanding can be beneficial to health care 
providers during counseling on uptake and timing of risk-reducing surgery. Until now, 
most studies are limited to investigating the uptake of risk-reducing surgery, but not its 
timing i.e. the age at which risk-reducing surgery is performed.
A limitation of previous research is that the impact of changes in guidelines in recent 
years, such as stopping ovarian cancer screening, on uptake and timing of risk-reducing 
surgery has yet to be determined69. Lastly, the impact of only few psychological factors 
has been thoroughly investigated. Among these factors, high cancer risk perception, 
anxiety and worry are repeatedly reported to be associated with the uptake of RRM and 
RRSO60,63,69,73,76,77. Other psychological factors (e.g. affect, perceived personal control) are 
likely to be at play, but have at best been sparsely investigated74. 
Part II:  
Psychological interventions alleviating menopausal symptoms after RRSO
Hormone replacement therapy 
The use of systemic HRT in young premenopausal women after RRSO is a balancing act 
between the effects of HRT on menopausal symptoms (e.g. hot flushes, vaginal dryness), 
sexual functioning, bone and cardiovascular health on the one hand and on breast cancer 
risk on the other42,79. The Dutch national guideline on hereditary and familial ovarian 
cancer advises to prescribe HRT after RRSO to women without a history of breast cancer 
until the age of 50 years9. 
Women who have had breast cancer or are older than 50 years at the time of RRSO are 
advised not to start HRT as the use of HRT in postmenopausal women is associated with 
increased breast cancer risk and contraindicated in breast cancer survivors9. The amount 
of studies on the safety of short-term use of topical vaginal estrogens in breast cancer 
survivors is limited. However, it is known that estrogen serum levels remain low during the 
use of topical vaginal estrogens80–82. Therefore it is likely that also in breast cancer survivors 
the benefits of short-term use of topical vaginal estrogens outweighs the risks9,82–84. 
Reported HRT use after RRSO ranges from 44 to 71% in young BRCA1/2 mutation carriers 
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without a history of breast cancer42,48,49,85–87. The main reason women cite for not using HRT 
after premenopausal RRSO is anxiety about increasing their risk of breast cancer42.
Effectiveness of HRT
The use of HRT after RRSO is associated with a decrease of frequency and severity of 
vasomotor symptoms, but HRT does not decrease these symptoms to the pre-surgical 
situation42,48,49,54,86,88. The findings concerning the effect of HRT on sexual complaints are 
more mixed. Although sexual symptoms, such as vaginal dryness, vaginal discomfort 
and pain during intercourse decrease, they are not completely alleviated with the use of 
HRT49. Other sexual symptoms after RRSO such as a decrease in sexual desire and sexual 
satisfaction do not improve with the use of HRT45,48,49,53,86,88. Topical vaginal estrogen is 
effective in improving vaginal dryness and improving sexual functioning in case of vaginal 
symptoms, but has no direct effect on sexual desire53.
HRT safety
Preliminary findings concerning the safety of systemic HRT indicate that short-term 
HRT use until the age of 50 years does not increase breast cancer risk in women who 
underwent RRSO. However, the use of HRT after menopausal age is associated with an 
increased breast cancer risk. HRT is contraindicated in breast cancer survivors, due to an 
increased risk of breast cancer recurrence89,90. More studies are needed on the safety of 
longer term HRT use in BRCA1/2 mutation carriers after RRSO42,54,91–97.
Alternative interventions 
As HRT does not alleviate menopausal and sexual symptoms completely and is advised 
against in breast cancer survivors and after the age of 50 years, a search commenced for 
alternative treatment options for these symptoms. In this search a myriad of modalities 
such as topical hormone therapy, transdermal testosterone, non-hormonal medication, 
complementary or alternative treatments, lifestyle/physical exercise and psychological 
interventions have been suggested94. Psychological interventions have recently gained 
more interest due to their favorable characteristics when compared to hormonal 
interventions. 
The main advantages of psychological interventions, such as mindfulness or cognitive 
based interventions, is firstly that they have no impact on cancer incidence or recurrence 
and secondly that they might impact frequency and perceived burden of symptoms (i.e. 
perceived bother) simultaneously98. Moreover, although no randomized trials have been 
performed in the RRSO population, psychological therapies seem to be beneficial in 
other populations, such as natural menopausal women, breast cancer survivors, women 
suffering from hypoactive sexual desire disorder or female sexual arousal disorder and 
women suffering from sexual complaints after gynecological cancer98–104. 
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Chapter outline 
The research presented in this thesis aims to improve our understanding of factors 
associated with the timing and uptake of risk-reducing surgery in women with a 
BRCA1/2 mutation and to investigate a non-hormonal alternative to HRT to mitigate the 
menopausal and sexual symptoms after surgical menopause, especially after RRSO in 
breast cancer survivors
Part I: Factors associated with the uptake of risk-reducing surgery 
Several factors are presumed to be associated with choosing RRM and RRSO in BRCA1/2 
mutation carriers. In chapter 2, the socio-demographic, medical and family characteristics 
possibly associated with the early timing of RRM in BRCA1/2 mutation carriers after DNA 
test disclosure were analyzed. Next to the above-mentioned factors, other psychological 
factors, such as emotional state, influence the decision for RRM. That is why in chapter 
3, the psychological factors associated with the intention to choose RRM were analyzed. 
This approach confirmed that the counsellor should pay attention to women’s perceived 
control and emotional state when counseling to women that are confronted with decision 
whether or not to choose RRM. 
Several studies reported that ovarian cancer screening lacked effectiveness for early 
detection of ovarian cancer, after which ovarian cancer screening was no longer offered. 
From that time onwards, the only ovarian cancer risk management option offered to 
BRCA1/2 mutation carriers is timely RRSO. In chapter 4, the effects of no longer offering 
ovarian cancer screening on the uptake and timing of RRSO was studied. In addition, other 
factors possibly associated with choosing RRSO were investigated. 
When taken together, the topics addressed in chapter 2, 3 and 4 help understand the 
uptake and timing of RRM and RRSO in women with a BRCA1/2 mutation and provide 
valuable insight in the topics that need to be addressed during counseling.
Part II: Psychological interventions alleviating menopausal symptoms after RRSO
The duration of menopausal symptoms after RRSO and what factors influence the severity 
and duration of these symptoms are currently not well known. To alleviate menopausal 
symptoms after RRSO, HRT is the most effective and most frequently offered option. 
Unfortunately, HRT is contraindicated in breast cancer survivors. Furthermore, HRT does 
not alleviate menopausal complaints and sexual sequelae to the premenopausal level. 
Therefore an alternative to HRT is necessary.
Chapter 5 describes a cross-sectional study on factors associated with the severity and 
duration of menopausal symptoms in previously premenopausal women at a mean of 
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7.9 years after RRSO. In chapter 6, a systematic literature review on the effectiveness 
of psychological interventions in reducing symptoms associated with menopause in 
natural or treatment-induced menopausal women is described. As there is a paucity of 
evidence on effectiveness with long-term follow-up of psychological interventions to 
alleviate menopausal and sexual complaints after RRSO, a randomized controlled trial 
was performed which is described in chapter 7. This randomized controlled trial aimed to 
investigate the short-term and long-term benefits of mindfulness-based stress reduction 
on the menopausal quality of life, sexual functioning and sexual distress in women after 
RRSO. The research described in chapter 6 and 7, provides a basis for the implementation 
of psychological interventions in a clinical setting after RRSO. Lastly, it provides suggestions 
towards future research on interventions alleviating sexual complaints after RRSO. 
Chapter 8 summarizes the main findings of this thesis in the context of current literature, 
addresses strengths and weaknesses and provides directions for further research on the 
topics of the abovementioned chapters.  
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Part 1
Factors associated with the uptake of risk-reducing surgery

The work described in this chapter was previously published in: 
Maturitas 2014 Feb; 77(2):180-4
Chapter 2
Risk-reducing mastectomy in BRCA1/2 mutation carriers: 
factors influencing uptake and timing
Catheleine M.G. van Driel, Yassir Eltahir, 
Jakob de Vries, Jan P.C. Jaspers, 
Jan C. Oosterwijk, Marian J.E. Mourits, 
Geertruida H. de Bock
Introduction: Strategies in case of high risk of breast cancer in BRCA1/2 mutation carriers 
are either intensive breast cancer screening or risk-reducing mastectomy (RRM). Both 
options have a high physical and psychosexual impact. The aim of this study is to investigate 
who chooses when to undergo RRM.
Methods: BRCA1/2 mutation carriers have been prospectively registered at the family 
cancer clinic between 1994 and 2011. Analyses were performed to assess the relation 
between characteristics of the BRCA1/2 mutation carriers and an earlier decision for RRM.
Results: A cumulative percentage of 35.6% of all women chose to undergo RRM within the 
first five years after disclosure of DNA test results. Women needed less time to choose for 
RRM measured from the first visit, if they were younger than 50 years of age (hazard ratio 
(HR)=2.67, 95% confidence interval (CI)=1.30-5.48) or had a mother who had had breast 
cancer (HR=1.51 95% CI=1.04-2.18). Also, women needed less time to choose for RRM in 
case of a previous breast cancer (HR=2.25, 95% CI=1.55-3.27). After a previous unilateral 
therapeutic mastectomy as a treatment for breast cancer, women needed less time to 
choose for RRM of the contralateral breast (HR=2.69, 95% CI=1.29-5.62) compared to women 
who had had breast-conserving therapy.
Conclusion: BRCA1/2 mutation carriers aged under 50, having a mother with breast cancer, 
who had previous unilateral breast cancer and previous unilateral therapeutic mastectomy 
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Introduction
Women with a BRCA1 or BRCA2 mutation have a significantly higher lifetime risk of 
developing breast cancer and are diagnosed at a younger age compared to the general 
population1–4. The lifetime risk at the age of 70 years for breast cancer was found to be 57-
65% for BRCA1 and 45-49% for BRCA2 mutation carriers1,2. 
BRCA1/2 mutation carriers have to make major decisions regarding the medical 
management of their increased breast cancer risk. To reduce the risk of death due to 
breast cancer, women can choose for risk-reducing mastectomy (RRM) or they can opt 
for intensive breast cancer screening aiming at early detection5,6. When performed at a 
young age, before the cancer risk is rising, RRM is associated with an actual breast cancer 
risk reduction of 90-95%7. However RRM has been associated with a negative impact on 
body image8. 
A review including 43 published articles identified three main types of factors that 
influence high-risk women’s decisions about risk-reducing strategies: a) medical and 
physical factors, b) psychological factors and c) social context factors. How these factors 
operate in women’s lives over time remained unknown9.
The purpose of this study was to identify baseline characteristics of BRCA1/2 carriers 
that opt for RRM early on following the disclosure of DNA test results. Identifying which 
characteristics influence the (early) decision for RRM can indicate important topics to be 
discussed during counselling.  
Methods
Patients
Women with an increased risk of carrying a BRCA1/2 mutation are referred to the 
clinical genetic department of the University Medical Centre Groningen for genetic risk 
assessment. Those that have a high cancer risk are followed-up at the Family Cancer Clinic 
(FCC) with a multidisciplinary team including clinical geneticists, surgical oncologists, 
gynaecological oncologists, plastic surgeons, social workers, nurse practitioners and a 
psychologist10. When visiting the FCC women were asked to give informed consent for 
entering their data into a prospectively maintained password protected FCC database. 
Protection of the patients’ identity was guaranteed by assigning study-specific, unique 
patient numbers. According to Dutch law no further Institutional Review Board approval 
was needed for this study. 
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Data collection
Women were included in this study if they were proven BRCA1/2 mutation carriers and 
had visited the FCC between April 1994 and November 2011 at least once. As according 
to Dutch guidelines RRM should preferably be offered to women from the age of 25 
years, only women ≥ 25 years of age were included in this study. We considered the 
disclosure date of the BRCA1/2 mutation to the patient as the first moment of contact 
and the last visit was considered to be the most recent visit to the FCC or the most recent 
visit to the FCC before RRM. The date of first contact and the date of the last visit were 
extracted from the (digital) patient files and used to calculate follow up times. For this 
study, characteristics concerning the patient as well as her family were collected. Patient 
characteristics concerned: age, mutation status and medical history. The medical history 
concerned previous breast and/or ovarian cancer, related treatment and risk reducing 
strategies. Patient characteristics were retrieved from the prospectively maintained FCC 
database. Family characteristics concerned: number and age of children and breast and/
or ovarian cancer within the family, both at the time of the first visit to the FCC. Family 
characteristics were derived from non-electronic clinical genetics records
Statistical analysis 
Survival analysis was chosen to demonstrate the course of decision making over time, 
since this method adjusts for variable follow-up time. Univariate and multivariate survival 
analyses were performed over the total group of women (women opting for RMM as 
well as opting for intensive breast cancer screening), in order to calculate the cumulative 
percentage of women undergoing RRM over time, hazard ratios (HR) and the 95% 
confidence intervals (CI) of the baseline characteristics where the timing of the decision 
to undergo RRM was considered dependent.
The disclosure date of the BRCA1/2 mutation to the patient was considered as the first 
moment of contact. The last moment of contact was considered to be the most recent visit 
or the most recent visit to the FCC before RRM. All tests were performed in SPSS Statistics 
20 package and all p-values were two-tailed and considered significant if p ≤ 0.05. 
Results
Description of the population 
From April 1994 until November 2011, 508 BRCA1/2 carriers ≥ 25 years of age had visited 
the FCC (Figure 2.1). Women were excluded if a RRM was performed before the first visit 
to the FCC (n=10), if they had had bilateral breast cancer or disseminated disease (n=38) 
and if their clinical files were not available (n=21) or were incomplete (n=30). Two women 
were excluded due to mild mental retardation and inability to make their own decisions 
(n=2). The number of women included in the analysis was 407. Patient characteristics are 
given in Table 2.1. 
Factors influencing uptake and timing of RRM
2
|   35 
Table 2.1: Characteristics of the study population at the time of DNA test disclosure and the 
uptake of RRM within 5 years of follow up (N=407).
Patient characteristic Frequencies at the time of 
DNA disclosure 
Cumulative uptake of 
RRM after 5 years 
Cumulative deferral of 




 <50 335/407 (82.3%) 38.4% 61.6%
 ≥50 72/407 (17.7%) 20.7% 79.3%
Mutation status
 BRCA1 255/407 (62.7%) 40.9% 59.1%
 BRCA2 152/407 (37.3%) 25.8% 74.2%
Children
 No 97/402 (24.1%) 27.9% 72.1%
 Yes 305/402 (75.9%) 38.1% 61.9%
Age youngest child
 <18 219/301 (72.8%) 43.5% 56.5%
 ≥18 82/301 (27.2%) 25.1% 74.9%
Mother with BC
 No 246/398 (61.8%) 30.6% 69.4%
 Yes 152/398 (38.2%) 44.2% 55.8%
Sister with BC
 No 300/399 (75.2%) 33.4% 66.6%
 Yes 99/399 (24.8%) 41.2% 58.8%
Mother with OC
 No 316/402 (78.6%) 38.7% 61.3%
 Yes 86/402 (21.4%) 24.6% 75.4%
Sister with OC
 No 357/395 (90.4%) 36.5% 63.5%
 Yes 38/395 (9.6%) 28.7% 71.3%
BC* in history
 No 291/407 (71.5%) 26.3% 73.7%
 Yes 116/407 (28.5%) 61.3% 38.7%
Number of BC*
 1 107/116 (92.2%) 61.8% 38.2%
 >1 9/116 (7.8%) 100.0% 0.0%
Therapy of first BC*
 Lumpectomy 45/112 (40.2%) 31.4% 68.6%
 Mastectomy** 67/112 (59.8%) 74.5% 25.5%
OC in history
 No 391/407 (96.1%) 36.2% 63.8%
 Yes 16/407 (3.9%) 19.6% 80.4%
N.A. not applicable, BC: breast cancer, OC: ovarian cancer, RRSO: risk reducing salpingo-oophorectomy, RRM: risk 
reducing mastectomy. 
*   This concerns unilateral breast cancer, RRM of the contralateral breast remained medical management 
option.
** Unilateral therapeutic mastectomy 
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Figure 2.1: Population fl owchart. All BRCA1/2 mutation carriers ≥ 25 years old entered in the 




















Determinants of the timing of the decision to undergo RRM
Within the fi rst fi ve years after disclosure of DNA test results a cumulative percentage 
35.6% women chose to undergo RRM (Table 2.1). In Table 2.2 it is shown that in the 
multivariate survival analysis, women younger than 50 years needed less time after 
counselling to decide for RRM than women > 50 years of age (HR=2.87 95% CI=1.40-5.92, 
p=0.0042). Furthermore women who had a mother with breast cancer needed less time to 
decide for RRM (HR=1.51 95% CI=1.04-2.18, p=0.031). Women previously diagnosed with 
unilateral breast cancer decided earlier for RRM of the contralateral breast than women 
without a breast cancer history (HR=2.54, 95% CI=1.74-3.70, p<0.001). Of the women with 
previous breast cancer, those who underwent therapeutic mastectomy as a therapy for 
a unilateral breast cancer needed less time to choose for RRM of the contralateral breast 
(HR=2.69, 95% CI=1.29-5.62, p=0.008) compared to women who had breast conserving 
therapy (Table 2.3). 
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Table 2.2: Analysis of the determinants of the timing of the decision for RRM (uni- and 
multivariate survival analysis) (N=407)
Patient characteristic Univariate HR (95% CI) p-value Multivariate HR (95% CI) p-value
Age 
 <50 2.67 (1.30-5.48) 0.007 2.87 (1.40-5.92) 0.004
 ≥50 1 1
Mutation status




 Yes 1.26 (0.81-1.97) 0.30
Age youngest child
 <18 2.18 (1.21-3.92) 0.01
 ≥18 1
Mother with BC
 No 1 1
 Yes 1.52 (1.05-2.20) 0.03 1.51 (1.04-2.18) 0.03
Sister with BC
 No 1
 Yes 1.35 (0.90-2.03) 0.15
Mother with OC
 No 1
 Yes 0.66 (0.41-1.07) 0.09
Sister with OC
 No 1
 Yes 0.74 (0.36-1.52) 0.42
BC* in history
 No 1 1
 Yes 2.25 (1.55-3.27) <0.001 2.54 (1.74-3.70) <0.001
OC in history




 Yes 1.20 (0.79-1.84) 0.39
BC: breast cancer, OC: ovarian cancer, RRSO: risk reducing salpingo-oophorectomy
* This concerns unilateral breast cancer, RRM of the contralateral breast remained medical management option. 
Result significant when p<0.05. 
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Table 2.3: Analysis of the determinants of the timing of the decision for RRM in the subgroup 
of BRCA1/2 carriers with previous breast cancer (N=116).*
Patient characteristic Univariate HR (95% CI) p-value
Age 
 <50 3.20 (1.15-8.92) 0.03
 ≥50 1
Mutation Status
 BRCA1 1.57 (0.76-3.25) 0.22
 BRCA2 1
Has children
 No 1.23 (0.64-2.38) 0.54
 Yes 1
Age youngest child




 Yes 1.62 (0.90-2.91) 0.11
Sister with BC
 No 1
 Yes 1.04 (0.56-1.92) 0.90
Mother with OC
 No 1
 Yes 0.60 (0.25-1.41) 0.24
Sister with OC
 No 1
 Yes 0.34 (0.08-1.42) 0.14
Number of BC**
 1 2.72 (0.37-19.89) 0.32
 >1 1
Therapy of first BC*
 Lumpectomy 1
 Mastectomy*** 2.69 (1.29-5.62) 0.008
OC in history
 No 1
 Yes 0.85 (0.20-3.50) 0.82
RRSO
 No 1
 Yes 1.84 (0.95-3.58) 0.07
BC: breast cancer, OC: ovarian cancer, RRSO: risk reducing salpingo-oophorectomy 
*  As in the multivariate results only therapy of first BC contributed, only univariate results are presented
**  This concerns unilateral breast cancer, RRM of the contralateral breast remained medical management 
option.
***  Unilateral therapeutic mastectomy
Result significant when p<0.05. 
Factors influencing uptake and timing of RRM
2
|   39 
Discussion 
Women needed less time to choose for RRM if they were younger than 50 years of age 
(HR=2.87 95% CI=1.40-5.92), had a mother with breast cancer (HR=1.51 95% CI=1.04-
2.18), had previous unilateral breast cancer (HR=2.54, 95% CI=1.74-3.70) and had a 
previous unilateral therapeutic mastectomy as a treatment for breast cancer (HR=2.69, 
95% CI=1.29-5.62). Contrarily to women who needed less time to decide for RRM, women 
who deferred RRM were older than 50 years of age, did not have a mother with breast 
cancer, did not have a previous unilateral breast cancer and had a previous unilateral 
lumpectomy as a treatment for breast cancer.
Previous studies showed that being a mother11–13, a previous breast cancer diagnosis13,14, 
previous mastectomy15, family history of breast cancer16–18 and younger age19 are 
associated with the decision for RRM. However, how these factors influence the timing of 
RRM remains unknown9.
Lodder et al. found it unresolved whether ‘young age’ or ‘having children’ is explanatory 
for the decision for RRM12. In our study having children or the age of the youngest child 
are not statistically significantly associated with an earlier decision to undergo RRM in 
the multivariate model, whereas an age < 50 years predisposes for RRM (HR=2.87 95% 
CI=1.40-5.92). This can be explained by the fact that we specifically take time to decision 
into account. A study that also took the time to the decision for RRM into account found 
similar results; younger than 60 years (HR=1.8, p=0.04) was associated with earlier RRM20. 
In this study, women aged 50 years or over are less likely to choose for RRM than younger 
women. One of the reasons might be that these women are counselled differently (doctors’ 
factor) counselling concerning RRM than younger women, because of a declining life 
expectancy gain from RRM with increasing age21. Another explanation could be that these 
women take their declining risk of breast cancer into account (patient ‘s factor).
Metcalfe et al. found that BRCA1/2 mutation carriers who underwent therapeutic 
mastectomy as the initial surgery for breast cancer were more likely to undergo 
contralateral RRM (p < 0.0001)22. In another study a statistically significant relation between 
breast conserving therapy and the decision to undergo contralateral RRM within 1 year of 
treatment for a primary unilateral breast cancer was found (OR = 1.7, 95% CI=1.21-2.36, 
p=0.0002)17. The authors explained this as a relation between failed breast-conserving 
therapy, followed by RRM.
Yi et al. found that there was an association between having one or more relatives with 
breast cancer and the decision for RRM (OR= 1.57; 95% CI = 1.19-2.09)18. King et al. also 
reported the association between having one or more relatives with breast cancer and the 
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decision for RRM (OR = 2.91, 95% CI = 2.33-3.63, p<0.0001)17. Metcalfe et al. differentiated 
between different types of relatives (sister, mother). They found that women who had 
a sister with breast cancer were more likely to undergo RRM (OR=2,4, p=0,003). Women 
who had a mother with breast cancer also showed a higher uptake of RRM, although this 
was not statistically significant (OR=1.7, p=0.07)16. In our study experience with cancer, 
whether this is personal experience or experience with affected family members, seem 
to be a factor closely related to the choice for RRM. It could be that these experiences 
increase the cancer specific worries23, which could make women more inclined to choose 
for RRM to avoid cancer. Another explanation for the relation between experiences 
with cancer and an earlier decision for RRM is that women are already familiar with the 
treatment options for breast cancer such as therapeutic mastectomy, thus making the 
step to RRM easier.
The strength of our study is that the analysis was performed in a large consecutive series 
of proven BRCA1 or BRCA2 mutation carriers, who were counselled in a similar protocolled 
way by members of one multidisciplinary team. Furthermore the majority of the data has 
been collected prospectively and the timing of the decision to undergo RRM is taken into 
account when analysing the determinants. Lastly, univariate and multivariate analyses 
were performed. The fact that this study is quantative in nature is next to strength, also a 
limitation because qualitative information on underlying motives for RRM is not included. 
Another limitation is that some data had to be gathered retrospectively when they were 
missing in the prospective database.
In conclusion, age younger than 50 years, having had a previous breast cancer or having 
affected family member seem to be factors in an (early) decision for RRM. Therefore it 
is advisable to discuss these factors during counselling. The speculations about the 
underlying motives of women who choose for RRM need to be clarified by longitudinal 
and qualitative research.
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Psychological factors associated with the intention to choose  
risk-reducing mastectomy in family cancer clinic attendees
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Objectives: Women seeking counseling because of familial breast cancer occurrence face 
difficult decisions, such as whether and when to opt for risk-reducing mastectomy (RRM) in 
case of BRCA1/2 mutation. Only limited research has been done to identify the psychological 
factors associated with the decision for RRM. This study investigated which psychological 
factors are related to the intention to choose for RRM.
Methods: A cohort of 486 cancer-unaffected women with a family history of breast cancer 
completed the following questionnaires prior to genetic counseling: the Cancer Worry Scale, 
Positive And Negative Affect Scale, Perceived Personal Control Scale, Hospital Anxiety and 
Depression Scale and State Anxiety Scale and questions regarding socio-demographic 
characteristics, family history, risk perception and RRM intention. Multivariate logistic 
regression was used to analyse the relation between psychological factors and women’s 
intention to choose for RRM.
Results: Factors associated with RRM intention were high positive affect (OR = 1.86, 95%CI 
= 1.12-3.08), high negative affect (OR = 2.52, 95%CI = 1.44-4.43), high cancer worry (OR = 
1.65, 95%CI = 1.00-2.72), high perceived personal control (OR = 3.58, 95%CI = 2.18-5.89), 
high risk-perception (OR = 1.85, 95%CI = 1.15-2.95) and having children (OR = 2.06, 95%CI 
= 1.21-3.50). 
Conclusion: Negative and positive affects play an important role in the intention for RRM. 
Furthermore, perceived personal control over the situation is associated with an intention 
for RRM. In addition to focusing on accurate risk communication, counseling should pay 
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Introduction
Women who carry a BRCA1 or BRCA2 mutation have a significantly higher risk of 
developing breast cancer and ovarian cancer and a higher risk to develop cancer earlier 
in life, compared to the general population1–5. BRCA1/2 mutation carriers have to decide 
between the two main risk management options to cope with the increased breast cancer 
risk: breast cancer surveillance aimed at the early detection of breast cancer, and risk-
reducing mastectomy (RRM) aimed at preventing breast cancer6,7. 
RRM results in an actual breast cancer risk reduction of about 90%8,9 and a decrease 
of general and breast cancer specific distress10, but is also associated with a negative 
impact on the sexual relationship, sexual satisfaction and body image10–12. Previously, 
sociodemographic (e.g. age, having children) and medical factors (e.g. mutation status, 
previous breast or ovarian cancer) have been found to influence the RRM decision-making 
process13. However, only limited research has been done to identify the psychological 
factors associated with the decision for RRM. So far, this research has primarily focused on 
perceived risk, anxiety & worry13. 
Specifically, a higher perceived cancer risk has been associated with uptake of, or intention 
to choose for RRM14–22. Furthermore, increased cancer-related distress, (cancer specific) 
anxiety and cancer worry are associated with a preference for RRM 17,19,21–23.
As several studies have emphasized the role of emotions and underlying affect on medical 
decision-making24–27, it is very plausible that more psychological factors, such as affect, 
influence the decision to undergo RRM. Identifying these factors is important for health 
care professionals providing decisional support and permits improved shared decision-
making. This study specifically investigated which psychological factors are related to the 
intention to choose for RRM. 
Methods
Population
The population of the current study was recruited in the context of the Breast Cancer Risk 
Communication (BRISC) study, which is a prospective study carried out in three academic 
familial cancer clinics in the Netherlands, i.e. University Medical Center Groningen, VU 
University Medical Center Amsterdam and Leiden University Medical Center28. Included 
in the BRISC study were women with a family history of breast cancer who sought first 
time genetic counseling concerning their breast cancer risk. A family history of breast 
cancer was defined as having at least one first-degree- and/or paternal second-degree 
family member with breast cancer. Women were not eligible to participate in this study 
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if they were younger than 18 years of age, suffered from evident psychiatric illness, were 
terminally ill or had a personal history of breast and/or ovarian cancer. 
Protection of the patients’ identity was guaranteed by assigning study-specific, unique 
patient numbers. The Medical Ethics Committees of all three centers approved the BRISC 
study protocol in 2005.
Data collection
All the data used in this paper was collected as part of the BRISC study of which recruitment 
took place between December 2005 and November 2007. Various questionnaires were 
completed at multiple time points. The questionnaires and administration procedure are 
described in more detail in the BRISC study protocol28. The questionnaires analyzed in 
the current study were filled out prior to intake consultation and concerned questions 
regarding sociodemographic factors (age, level of education, having children, relationship 
status, religiousness), family breast cancer history (first degree relatives with breast 
cancer), psychological scales (Cancer Worry Scale (CWS)29, Positive And Negative Affect 
Scales (PANAS-PA and PANAS-NA)30, State-Trait Anxiety Inventory-state (STAI-state)31, 
Hospital Anxiety and Depression Scales (HADS-A and HADS-D)32 and Perceived Personal 
Control (PPC)33, risk perception and RRM intention. 
To determine risk perception, women’s appraisal of perceived breast cancer risk was 
assessed independently of actual risk that was going to be determined and communicated 
after intake. Women were asked to appraise their perceived breast cancer risk independent 
of their actual risk. Women could select an answer on a 7-point scale, the options ranging 
from “very small” (1) to “very large” (7). Women were considered to have a high risk-
perception if they selected “large” or “very large” as the answer. 
To determine RRM intention, women answered the following question: “If you would be 
a proven BRCA1/2 mutation carrier, would you choose for RRM?”. Women could select an 
answer on a 7-point Likert-type scale, with options ranging from “No, definitely not” to 
“yes, definitely”. Women were considered to have the intention to choose for RRM if they 
selected “probably yes”, “yes” or “yes, definitely” as the answer.
Statistical analysis 
All questionnaires were scored in accordance with the commonly used scoring manuals. 
Mean imputation was used when questionnaires were incomplete but at least half of the 
items were completed. If this criterion was not met, the case was deleted from the analysis.
Dichotomization of each measure was done in order to compare the highest scoring 
subgroup to the lowest scoring subgroup. The CWS, PANAS and HADS were dichotomized 
using cut-off points as previously defined in literature. The CWS score was considered low 
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if ≤13, and high if ≥1434. The PANAS-PA score was considered low if ≤35 and high if ≥36. 
The PANAS-NA score was considered low if ≤17 and high if ≥1835. Both the HADS-A and 
HADS-D scores were considered low if ≤7 and high if ≥836. The remaining questionnaires 
were dichotomized using the median value to create equally sized groups. 
To investigate the association between the baseline characteristics and the intention to 
choose for RRM a univariate and multivariate logistical regression was done to calculate 
the odds ratios (OR) and the 95% confidence intervals (95% CI), where intention to choose 
for RRM was considered dependent. 
All tests were performed in SPSS Statistics 20 package and all p-values were two-tailed 
and considered significant if p < 0.05.
Results
Description of the population 
The analyses included 486 women and population characteristics are given in Table 3.1. 
Of these women, 125 (25.7%) women had an intention to choose for RRM when indicated 
and 260 (54.5%) women perceived their breast cancer risk as high (Table 3.1). 
Predictors of the intention to choose for RRM
In the univariate analysis, having children (OR = 2.21, 95%CI = 1.35-3.60), not being highly 
educated (OR = 1.59, 95%CI = 1.03-2.45), a high perceived risk (OR = 1.89, 95%CI = 1.25-
2.88), experiencing high cancer worry (OR = 2.20, 95%CI = 1.45-3.32), a high negative affect 
(OR = 1.88, 95%CI = 1.20-2.95) and a high perceived personal control (OR = 3.41, 95%CI 
= 2.16-5.36) were all statistically significantly associated with the intention to choose for 
RRM (Table 3.2).
In the multivariate analysis, women who had children (OR = 2.06, 95%CI = 1.21-3.50), had 
a high perceived-risk (OR = 1.85, 95%CI = 1.15-2.95), experienced high cancer worry (OR 
= 1.65, 95%CI = 1.00-2.72), had a high positive affect (OR = 1.86, 95%CI = 1.12-3.08), had 
a high negative affect (OR = 2.52, 95%CI = 1.44-4.43) and had high perceived personal 
control (OR = 3.58, 95%CI = 2.18-5.89) had statistically significant greater intention to 
choose for RRM (Table 3.3).
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Table 3.1: Patient characteristics prior to genetic counseling in women with and without 
intention to choose for RRM (N=486)








 < 40 240 (49.4) 54 (22.5) 186 (77.5)
 ≥ 40 246 (50.6) 71 (28.9) 175 (71.1)
Having children
 No 153 (31.5) 25 (16.3) 128 (83.7)
 Yes 332 (68.5) 100 (30.1) 232 (69.9)
Has first degree relative with BC
 No 107 (28.9) 28 (26.2) 79 (73.8)
 Yes 263 (71.1) 59 (22.4) 204 (77.6)
Highly educated2
 No 282 (59.1) 82 (29.1) 200 (70.9)
 Yes 195 (40.9) 40 (20.5) 155 (79.5)
Married or cohabiting
 No 98 (20.2) 21 (21.4) 77 (78.6)
 Yes 387 (79.8) 104 (26.9) 283 (73.1)
Actively religious
 No 348 (72.2) 90 (25.9) 258 (74.1)
 Yes 134 (27.8) 34 (25.4) 100 (74.6)
Perceived risk
 Low 217 (45.5) 43 (19.8) 174 (80.2)
 High 260 (54.5) 81 (31.2) 179 (68.8)
Cancer worry^
 Low 286 (59.1) 56 (19.6) 230 (80.4)
 High 198 (40.9) 69 (34.8) 129 (65.2)
Positive affect^
 Low 254 (54.2) 55 (21.7) 199 (78.3)
 High 215 (45.8) 63 (29.3) 152 (70.7)
Negative affect^
 Low 344 (73.3) 75 (21.8) 269 (78.2)
 High 125 (26.7) 43 (34.4) 82 (65.6)
State anxiety+
 Low 244 (50.7) 56 (23.0) 188 (77.0)
 High 237 (49.3) 66 (27.8) 171 (72.2)
Hospital anxiety^
 Low 403 (82.1) 97 (24.1) 306 (75.9)
 High 83 (17.9) 28 (33.7) 55 (66.3)
Hospital depression^
 Low 436 (89.9) 109 (25.0) 327 (75.0)
 High 49(10.1) 16 (32.7) 33 (67.3)
Perceived personal control+
 Low 226 (47.2) 32 (14.2) 194 (85.8)
 High 253 (52.8) 91 (36.0) 162 (64.0)
RRM=risk-reducing mastectomy.
BC=breast cancer
1: Based on risk estimate provided by genetic risk counselor at intake consultation.
2: Yes: Vocational or research university 
#: Some variables have missing cases, therefore the cases of some variables do not add up to 486.
+: Cut-off point based on median/equal group sizes. 
^: Cut-off point based on a previously defined score from literature. 
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Table 3.2: Univariate logistic regression of the predictors of RRM intention, prior to genetic 
counseling (N=486)
Patient characteristics Univariate logistical regression
  OR 95% CI
Age (years)
 < 40 1
 ≥ 40 1.40 0.93-2.11
Having children
 No 1
 Yes 2.21** 1.35-3.60
Has first degree relative with BC
 No 1.25 0.73-2.06
 Yes 1
Highly educated2




 Yes 1.35 0.79-2.29
Actively religious




 High 1.89** 1.25-2.88
Cancer worry^
 Low 1
 High 2.20** 1.45-3.32
Positive affect^
 Low 1
 High 1.50 0.99-2.28
Negative affect^
 Low 1
 High 1.88** 1.20-2.95
State anxiety+
 Low 1
 High 1.30 0.86-1.96
Hospital anxiety^
 Low 1
 High 1.61 0.97-2.67
Hospital depression^
 Low 1
 High 1.45 0.77-2.75
Perceived personal control+ 
 Low 1
 High 3.41** 2.16-5.36
RRM=risk-reducing mastectomy.
BC=breast cancer
1: Based on risk estimate provided by genetic risk counselor after intake consultation.
2: Yes: Vocational or research university 
*: p<0.05
**: p<0.01
+: Cut-off point based on median/equal group sizes. 
^: Cut-off point based on a previously defined score from literature. 
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Table 3.3: Multivariate logistic regression of the predictors of RRM intention, prior to genetic 
counseling (N=453)
Patient characteristics Univariate logistical regression
  OR 95% CI
Having children
 No 1
 Yes 2.06** 1.21-3.50
Risk perception
 Low 1
 High 1.85* 1.15-2.95
Cancer worry^
 Low 1
 High 1.65* 1.00-2.72
Positive affect^
 Low 1
 High 1.86* 1.12-3.08
Negative affect^
 Low 1
 High 2.52** 1.44-4.43
Perceived personal control+
 Low 1




+: Cut-off point based on median/equal group sizes.
^: Cut-off point based on a previously defined score from literature.
Discussion 
The objective of this study was to identify psychological factors associated with the 
intention to choose for RRM, as research so far has mainly been limited to sociodemographic 
and medical factors.
Of the participants 25.7% had an intention to choose for RRM if indicated due to a BRCA1/2 
mutation. Next to having children, the following psychological factors were associated 
with the intention to choose for RRM: high positive and high negative affect, experiencing 
a high level of personal control, experiencing a high level of cancer worry and high cancer 
risk-perception. 
A novel finding of this study is that higher levels of negative affect, characterized by feelings 
of distress and higher levels of positive affect, characterized by feelings of energy and 
self-esteem, being distinctive dimensions, both play an important role in the intention to 
choose for RRM. Slovic et al. introduced the theoretical framework of the affect heuristic, 
which describes the importance of affect in guiding judgments and decisions37. This 
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framework asserts that mental representation of events become “tagged” with an affective 
meaning constructed of people’s positive and/or negative previous experiences with this 
event. Thereby, relying on affect can be a very quick and efficient way to weigh the pros 
and cons of a situation, especially in case of a very complex and uncertain situation37. The 
situation of having a BRCA1/2 mutation and having to decide on whether or not to choose 
for RRM can very well be characterized as a complex and uncertain situation and therefore 
the role of affect becomes more apparent in this decision-making process.  A review on 
affect and cancer risk perception concluded that communicating factual risk information 
not only improves counselees’ factual knowledge but also elicits an affective reaction, or 
in other words an emotional meaning is assigned to the presented factual information38. 
This emotional reaction can be more influential in medical decision-making than factual 
knowledge38. 
The second novel finding of this study is that an increased perceived personal control is 
positively correlated with the intention to choose for RRM. The fact that perceived personal 
control over a situation might induce a stronger intention to undertake corresponding 
actions is described by the theory of planned behavior39. This theory asserts that the 
intention to engage in behavior is determined by a person’s attitude toward the behavior, 
perception of social norms and perceived control39 and is widely used to explain the 
decision-making process40. Perceived personal control is fundamental to adequate coping 
with health issues such as genetic susceptibility to breast cancer41. 
This study corroborates the findings of several previously performed studies concerning 
predictors of RRM (Table 3.4). Firstly, the psychological factors associated with RRM 
intention that are corroborated by this study are high perceived-risk14–21,42–44 and cancer 
worry 17,19,43 are associated with an intention to choose for RRM. These findings suggest 
that apart from actual risk, the way women perceive their risk influences their intention to 
choose for RRM. This is underpinned by the fact that people tend to base their decisions on 
their interpretation of literal information in addition to basing it on the literal information 
itself26. This interpretation is shaped, among other things, by emotions such as worry26,45.  
Secondly, our study found that the socio-demographic factor having children was 
associated with the intention to choose for RRM. Multiple previous studies have shown 
that women who have children are more inclined to choose for RRM18,20,46–50. 
The RRM intention percentage found in this study is comparable to the percentages of 
19% and 23% found in previous studies on the pre-genetic counseling intention for RRM 
in women with an increased breast cancer risk21,22. 
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Table 3.4. Recent* studies on predictors of RRM in high risk populations
Author & year Study population
n, BC (un)affected, eligible# 
for genetic counseling or 
tested. 
Outcome type of RRM
- RRM intention or uptake & 
contralateral of bilateral  
- Assessment of predictors and RRM 
before or after genetic counseling
- Type of analysis 
Predictors statistically significantly 
associated with RRM 
Tong et al., 201521 696 BC affected and 
unaffected women 
eligible for genetic 
counseling.
- Contra/bilateral RRM intention  
- Prior to genetic counseling 
- Multivariate  logistic  regression 
- Younger age
- Higher education
- Greater perceived BC risk
- Greater distress
Portnoy et al., 
201543
BC affected and 
unaffected BRCA mutation 
carriers
- Contra/bilateral RRM uptake 
- After genetic counseling 
- Multivariate  logistic  regression
- Greater perceived BC risk 
- Greater BC worry 
Elsayegh 
et al., 201453 
165 women with DCIS 
eligible for genetic 
counseling
- Contralateral RRM uptake  
- After genetic counseling
- Multivariate logistic regression
- Younger age
- Having relatives with OC
- Having BRCA mutation
van Driel et al., 
201454
407 BC affected and 
unaffected BRCA mutation 
carriers
- Contra/bilateral RRM uptake
- After genetic counseling 
- Multivariate cox regression
- Younger age
- Having a mother with BC 
- Previous BC
- Therapeutic unilateral 
mastectomy 
Singh et al., 201355 136 BC unaffected BRCA 
mutation carriers
- Bilateral RRM uptake 
- After genetic counseling
- Multivariate logistic regression
- 1st and 2nd family BC death
- Having children
- More recent genetic testing 
King et al., 201344 284 women ≤ 50y with 
BC eligible for genetic 
counseling 
- Contralateral RRM intention 
- Prior to genetic counseling
- Multivariate linear regression
- Higher neuroticism
- Greater perceived new BC risk 
- Higher risk of BRCA mutation 
- Any surgical recommendation 
- Lower lumpectomy preference
Schwartz et al., 
201223
108 BC affected and 
unaffected BRCA mutation 
carriers
- Contra/bilateral RRM uptake 
- Predictors prior to genetic 
counseling
- RRM uptake after genetic 
counseling.
- Multivariate logistic regression
- Intact ovaries  
- Greater anxiety 
Haroun et al., 
201142
246 BC unaffected BRCA 
mutaion carriers  
- Bilateral RRM uptake
- After genetic counseling
- T-test and chi-squared  test
- Younger age 
- Greater perceived BC risk
Julian-Reynier et 
al., 201050
244 BC unaffected BRCA 
mutation carriers 
- Bilateral RRM uptake
- Predictors prior to & after genetic 
counseling
- RRM uptake after genetic 
counseling.
- Multivariate cox regression
Prior to genetic testing:
- Having children < 15 y at testing
- Having FDR with BC < 50 years
- RRM intention before BRCA 
disclosure 
After genetic testing:
- Impact of BRCA disclosure 
Skytte et al., 201049 306 BC unaffected BRCA 
mutation carriers
- Bilateral RRM uptake
- After genetic testing 
- Multivariate cox regression
- Younger age
- Having children 
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Kiely et al., 201056 1018 BC affected women 
with a BC family history, 
included tested BRCA 
mutation carriers and 
untested women. 
- Contralateral RRM uptake 
- Before and after genetic counseling†
- Multivariate cox regression 
- Younger age at BC diagnosis 
- BC diagnosis more recent 
- Therapeutic unilateral 
mastectomy 
- Underwent RRSO
Evans et al., 200957 211 BC 
unaffected BRCA mutation 
carriers and 3,515 women 
at >25% lifetime risk of 
breast cancer without 
known mutations.
- Bilateral RRM uptake 
- After genetic counseling
- Univariate cox regression
- BRCA mutation
- Younger age at testing (in BRCA  
mutation carriers)
Beattie et al., 200958 237 BC affected and 
unaffected BRCA mutation 
carriers
- Contra/bilateral RRM uptake
- After genetic counseling 
- Univariate cox regression
- Younger age 
- Previous BC
- RRSO
* Since publication of Howard  et al., Women’s decision-making about risk-reducing strategies in the context 
of hereditary breast and ovarian cancer: a systematic review. J Genet Couns 2009, 18: 578–97. 10.1007/s10897-
009-9245-9. Influential factors identified in this narrative review: having children, perceived cancer risk, cancer-
related distress, anxiety, worry & family history of BC/OC. #: Eligibility criteria differed per study (e.g. based on 
family history, risk of carrying BRCA mutation, age of first breast cancer etc.),  †: Population was partly untested, 
BC: breast cancer, DCIS: ductal carcinoma in situ, OC: ovarian cancer, FDR: first degree relative, RRSO: risk-
reducing salpingo-oophorectomy. 
Strengths of this study are that the analyses were done in a large sample of women, 
making it possible to identify multiple independent associations. Next to that, a large 
range of psychological factors and questionnaires were taken into account.
It could not be studied whether psychological factors associated with the intention to 
undergo RRM and actual RRM uptake change after genetic counseling. However, previous 
studies have shown that the intention whether or not to choose for RRM prior to genetic 
testing predicts actual uptake of RRM51,52. Furthermore, previous studies show that if a 
woman prefers RRM, this preference remains stable over time. Lastly, the data of this study 
has been collected between 2005 and 2007. It could be that the factors influencing the 
decision for RRM have evolved in recent years. 
The results of this study signify that the intention to choose for RRM is influenced, amongst 
other factors, by psychological factors i.e. cognitive and affective factors. 
With regard to affect, next to supplying precise and literal risk information in order to 
achieve accurate risk-perception, counseling should include the clarification of counselees’ 
affective response, ensuring it fits the intended message goals, either by routine discussion 
or specific interventions. Furthermore, counselors’ awareness of the influence of perceived 
control on the decision making process incites focus on specific topics and informational 
needs that enhance counselees’ sense of control and thereby coping capabilities. 
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Supplying decisional support that integrates the role of affect and perceived control in the 
decision-making process ensures medically adequate decisions and the optimal support 
of counselees in other respects such as psychological wellbeing and satisfaction, thereby 
facilitating meaningful shared decision-making.
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Stopping ovarian cancer screening in BRCA1/2 mutation carriers:
effects on risk management decisions & outcome of 
risk-reducing salpingo-oophorectomy specimens
Catheleine M.G. van Driel, Geertruida H. de Bock, 
Henriette J.G. Arts, Aisha S. Sie, 
Harry Hollema, Jan C. Oosterwijk, 
Marian J.E. Mourits
Introduction: Ovarian cancer screening (OCS) for BRCA1/2 mutation carriers was stopped 
in our family cancer clinic in 2009 because of its ineffectiveness. The study objective was to 
investigate the effect of stopping OCS on the timing and uptake of risk-reducing salpingo-
oophorectomy (RRSO) and on the percentage of occult cancers in the specimens. 
Methods: 419 BRCA1/2 mutation carriers were recruited between January 1999 and June 
2013. Uptake, timing and the outcome of the RRSO specimens before stopping OCS (period 
I) were compared to those after stopping OCS (period II). 
Results: The percentage of women undergoing RRSO within the recommended age range 
increased from 81% to 95%. Receiving DNA test results in period II independently predicted 
a shorter time interval to RRSO (hazard ratio: 2.48, 95% confidence interval: 1.81-3.39). The 
incidence of detecting occult cancers in RRSO specimens before and after stopping OCS was 
1.3% and 1.8% respectively and was not statistically significantly different.
Conclusion: The presentation of risk management options to women may influence their 
decision. The increased patient awareness of the ineffectiveness of OCS could have led 
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Introduction 
Women who carry a BRCA1/2 mutation have a high lifetime risk of developing ovarian 
cancer. A recent prospective study estimated a lifetime risk for ovarian cancer in BRCA1 
and BRCA2 mutation carriers of 59% (95% Confidence interval (CI) = 43-76%) and 16.5% 
(95% CI = 7.5-34%), respectively1. Since 2007, the perspective on optimal risk management 
for ovarian cancer in BRCA1/2 mutation carriers has changed in response to studies which 
reported that ovarian cancer screening (OCS) lacked effectiveness for early detection of 
ovarian cancer in these mutation carriers2–5. In light of these findings and in advance of 
national guideline changes, our family cancer clinic stopped offering OCS in October 
2009. From that time onwards, the only ovarian cancer risk management option offered 
to BRCA1/2 mutation carriers is risk-reducing salpingo-oophorectomy (RRSO). RRSO is 
recommended for patients younger than the age at which the ovarian cancer incidence 
rises, 35 to 40 years for BRCA1 mutation carriers and 40 to 45 years for BRCA2 mutation 
carriers, provided that the patients have completed their childbearing6–8. RRSO reduces 
the risk of ovarian cancer with 80-90% when performed within the recommended age 
range9–14. Moreover, RRSO may also reduce the risk of breast cancer in premenopausal 
women9–14. However, RRSO is also associated with adverse effects in premenopausal 
women due to acute surgical menopause15–17.  
Both younger age and nulliparity at the time of receiving the DNA test result were factors 
related to a longer interval between receiving DNA test results and RRSO18–21. In the 
aforementioned studies BRCA1/2 mutation carriers could choose between OCS and RRSO. 
Our objective was to investigate the effect of stopping OCS on the timing and uptake of 
RRSO and on the percentage of occult cancers found in the RRSO specimens. 
Methods
Study design and patients 
A prospective cohort design was used to investigate the effect of stopping OCS on the 
timing and uptake of RRSO and on the percentage of occult cancers found in the RRSO 
specimens. This study was performed in BRCA1/2 mutation carriers who visited the family 
cancer clinic at least once between 1999 and June 2013. All the women who visited the 
family cancer clinic in this time period were asked for informed consent before entering 
their data into the prospectively maintained, password protected family cancer clinic 
database. Protection of the patient’s identity was guaranteed by assigning study-specific, 
unique patient numbers. According to Dutch law, no further Institutional Review Board 
approval was needed for our study. 
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Setting 
Women at increased risk for hereditary ovarian and/or breast cancer are referred to 
the family cancer clinic of the University Medical Center Groningen for genetic risk 
assessment22. Proven BRCA1/2 mutation carriers are then followed-up at the family cancer 
clinic, which consists of a multidisciplinary team including gynecological oncologists, 
surgical oncologists, clinical geneticists, plastic surgeons, nurse practitioners and 
psychologists who offer integrated care22. 
Change in ovarian risk managing protocol 
All BRCA1/2 mutation carriers receive standardized counseling about the increased 
ovarian cancer risk, first from a clinical geneticist in the course of DNA testing, and 
subsequently from a gynecological oncologist at the family cancer clinic22. Before October 
1, 2009 (period I) women were offered OCS (consisting of an annual gynecological exam, 
transvaginal ultrasound and CA125 testing from the age of 35 years onwards) or RRSO 
from the age of 35 to 40 years for BRCA1 mutation carriers and 40 to 45 years BRCA2 
mutation carriers, given that they had completed their child-bearing22,23. Starting October 
1, 2009 (period II) our family cancer clinic stopped offering OCS because of its proven 
ineffectiveness in reducing morbidity and mortality of ovarian cancer2–5. In period II, RRSO 
was the only risk management option advised for all BRCA1/2 mutation carriers22,23, advice 
that was combined with information addressing the consequences of acute menopause 
after RRSO22. The waiting time for surgery remained stable during the follow-up time of 
this study, approximately three to six weeks.  
Data collection 
The following data were collected for each patient: date of birth, number of children, 
personal history of breast cancer, mother and/or sisters with breast and/or ovarian 
cancer, mutation status (BRCA1 or 2), date on which DNA test results were received by 
the patient, chosen ovarian cancer risk management option (RRSO or no RRSO), date 
of RRSO and outcome of the RRSO specimen. Age, mutation status and medical history 
were retrieved from the prospectively maintained family cancer clinic database. When the 
aforementioned variables were missing in the family cancer clinic database, they were 
retrieved from the patient’s medical records. Family history, number of children and date 
on which DNA test results were received were always retrieved from the patient’s medical 
records. Data was retrieved from the prospective family cancer clinic database and patient 
medical records in July 2013. The number of children was grouped into one child or less 
and two or more children to ensure equal group sizes. Age at the time of DNA test result 
disclosure was stratified on the basis of whether a woman had or had not reached the 
recommended age for RRSO. The recommended age range was defined as 35 to 40 years 
for BRCA1 mutation carriers and 40 to 45 years for BRCA2 mutation carriers. 
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Statistical analysis
Follow-up time was calculated as the time interval between DNA test result disclosure and 
the date at the last follow-up or, in the case of RRSO, date of surgery. Women who received 
their DNA test results in period I were compared to women who received their DNA test 
results in period II in terms of cumulative uptake of RRSO. 
Multivariable survival analyses were performed to estimate hazard ratios (HRs) and 
related 95% confidence intervals (95%CIs) that could be used to assess if the period in 
which patients received their DNA test results (i.e. period I or period II) was independently 
associated with the interval between DNA test result disclosure and RRSO. All tests were 
performed in SPSS Statistics 20 package and all p-values were two-tailed and considered 
statistically significant if p ≤ 0.05. 
Results 
Population
Between January 1999 and June 2013, 541 BRCA1/2 mutation carriers visited the family 
cancer clinic at least once. Of these, 24 (4.4%) women had already undergone bilateral 
salpingo-oophorectomy (for any reason) and 12 (2.2%) women had developed ovarian 
cancer before the date of receiving DNA test results. In total, 84 (15.5%) patient files were 
either unavailable (n=38, 7.0%) or incomplete (n=46, 8.5%). Two (0.4%) women were 
unable to make their own decisions due to a mental incapacity and were excluded from 
the analysis. A final total of 419 (77.5%) women were included in our analyses. The women 
excluded did not statistically significantly differ from the women included in the study in 
terms of mutation status (BRCA1 or BRCA2) or having a personal history of breast cancer.
A total of 319 women received their DNA result in period I and 100 women received it 
in period II (Table 4.1). In period I, 35% (N=113) of the women had a BRCA2 mutation, 
whereas in period II, 55% (N=55) of the women had BRCA2 mutation.
The follow-up time (time from receiving DNA test results to RRSO or last follow-up) ranged 
from zero to 174 months, with a median follow up time of six months. In period I, the 
follow up time ranged from zero to 174 months (median eight months) with a median 
time to RRSO of eight months. In period II, the follow up time ranged from zero to 37 
months (median three months) with a median time to RRSO of four months.  
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Table 4.1. Characteristics of the study population at the time they received DNA test results 
in period I and period II (n=419) 
Patient characteristics Frequencies or mean values
  Period I# (n = 319) Period II# (n = 100)
Age, mean (SD) (range) 39.2 (10.5) (19-71) 39.4 (10.0) (23-60)
Mutation status, n (%)
 BRCA1 206 (65) 45 (45)
 BRCA2 113 (35) 55 (55)
Number of children, n (%)
 0-1 124 (39) 43 (43)
 ≥ 2 195 (61) 57 (57)
Mother with BC*, n (%)
 No 206 (65) 62 (62)
 Yes 113 (35) 38 (38)
Sister with BC*, n (%)
 No 237 (74) 84 (84)
 Yes 82 (26) 16 (16)
Mother with OC**, n (%)
 No 260 (82) 85 (85)
 Yes 59 (18) 15 (15)
Sister with OC**, n (%)
 No 293 (92) 97 (97)
 Yes 26 (8) 3 (3)
Personal history of BC*, n (%)
 No 233 (73) 81 (81)
 Yes 86 (27) 19 (19)
Follow-up time in months, median (range) 8 (0-174) 3 (0-37)
*  BC: breast cancer **OC: ovarian cancer
#: Period I: Before 1/10/2009, (OCS offered),
    Period II: After or at 1/10/2009. (OCS not offered any more)
Uptake of RRSO
In period I, the overall cumulative uptake of RRSO within 12 months after DNA test result 
disclosure was 53% and this increased to 85% in period II (Table 4.2). The cumulative 
uptake for women with two children or more increased from 66% to 97% and the uptake 
for women who reached the recommended age increased from 77% to 91%. 
Timing of RRSO
Out of the 419 women in this study, 322 women had either not yet reached the 
recommended age range for RRSO or were already past this age at the time they 
received their DNA test result. The remaining 97 women were under follow-up during the 
recommended age range for RRSO. Out of these women, 81% (61/75) underwent RRSO 
within the recommended age range in period I. This percentage increased to 95% (21/22) 
in period II (Table 4.3). 
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Table 4.2. Cumulative uptake of RRSO 12 months after DNA test result disclosure for two 
groups: women who received their DNA test results in period I or in period II (n=419)
Patient characteristics Cumulative uptake of RRSO 12 months after receiving DNA test results




 No 13 56
 Yes 77 91
Mutation status
 BRCA1 51 79
 BRCA2 59 89
Number of children
 0-1 31 59
 ≥ 2 66 97
Mother with BC*
 No 59 91
 Yes 45 72
Sister with BC*
 No 45 83
 Yes 75 91
Mother with OC**
 No 55 85
 Yes 49 81
Sister with OC**
 No 51 84
 Yes 81 100
Personal history of BC*
 No 49 83
 Yes 67 91
×: The recommended age range for BRCA1 and BRCA2 mutation carriers is from 35 to 40 years and 
     from 40 to 45 years, respectively. 
#: Period I: Before 1/10/2009, (OCS offered),
     Period II: On or after 1/10/2009, (OCS no longer offered)
* BC: breast cancer **OC: ovarian cancer
A shorter interval between receiving DNA test results and RRSO was independently 
associated with receiving DNA test results in period II (HR = 2.48, 95%CI = 1.81-3.39), with 
having reached the recommended age for RRSO (HR = 4.27, 95%CI = 3.12-5.84) and with 
having two or more children (HR = 2.00, 95%CI = 1.51-2.65) (Table 4.4). Mutation status, a 
mother with breast or ovarian cancer, a sister with breast or ovarian cancer, and a personal 
history of breast cancer were not independently statistically significantly associated 
with a shorter interval between receiving DNA test results and RRSO in the multivariable 
analysis. 
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Table 4.3. Uptake of RRSO within the recommended age range× in women who were under 
follow-up within the recommended age range in period I and II (N=97)
Period I# (n=75) Period II# (n=22)
RRSO within recommended age range×, n (%)
 No 14 (19) 1    (5)
 Yes 61 (81) 21 (95)
×: The recommended age range for BRCA1 and BRCA2 mutation carriers is from 35 to 40 years and 
    from 40 to 45 years, respectively. 
#: Period I: Before 1/10/2009, (OCS and RRSO offered),
    Period II: On or after 1/10/2009. (OCS no longer offered)
Table 4.4. Analysis of the predictors of the time interval between receiving DNA test results 
and the date of RRSO (multivariable survival analysis) (N=419)
Multivariable survival analysis
  HR 95% CI
Reached recommended age×
 No 1
 Yes 4.27+ 3.12-5.84
Number of children
 0-1 1
 ≥ 2 2.00+ 1.51-2.65
Period of receiving DNA test results
 Period I# 1
 Period II# 2.48+ 1.81-3.39
×: The recommended age range for BRCA1 and BRCA2 mutation carriers is from 35 to 40 years and from 40 to 45 
years, respectively. 
+: p<0.01; 
#: Period I: Before 1/10/2009, (OCS and RRSO  offered),
    Period II: On or after 1/10/2009. (OCS no longer offered)
Outcomes of RRSO specimens 
During period I, three occult cancers were recorded in 220 RRSO specimens (1.3%) (Table 
4.5). All cases concerned BRCA1 mutation carriers ranging from 41 to 60 years of age. After 
staging, two ovarian cancer cases, FIGO stage IIC and IIIB and one fallopian tube cancer 
case, FIGO stage IC were found. During period II, one occult cancer was recorded in 54 
RRSO specimens (1.8%). This case concerned a serous tubal intraepithelial carcinoma 
(STIC) in a BRCA2 mutation carrier aged 57 years.
Discussion 
The objective of this study was to investigate the effect of stopping OCS on the timing and 
uptake of RRSO and on the percentage of occult cancers found in the RRSO specimens. 
We found that after stopping OCS the percentage of women who underwent RRSO within 
the recommended age range increased from 81 to 95%. Only one woman did not perform 
RRSO within the recommended age range in period II. This concerned a BRCA1 mutation 
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Table 4.5. Outcomes of RRSO specimen (n = 274/419†)
Frequencies or mean values
Period I# (n = 220/319†) Period II# (n = 54/100†)
Histopathology, n (%)
 Benign 217 (98.7) 53 (98.2)
 Malignant 3     (1.3) 1   (1.8)
 
 FIGO stage,    
 age, mutation
  - IC, 60y, BRCA1
  - IIIB, 44y, BRCA1
  - IIC, 41y, BRCA1
  - STIC*, 57y, BRCA2
†: Out of 419 cases, 274 women chose RRSO. The number of RRSOs divided by the total population in each 
period does not give the same percentages as mentioned in table 4.2, because table 4.2 shows cumulative 
percentages. Furthermore, the number of RRSOs is lower in period II due to a shorter follow-up time. 
#: Period I: Before 1/10/2009, (OCS and RRSO were offered),
    Period II: On or after 1/10/2009. (OCS no longer offered)
*: STIC: Serous Tubal Intraepithelial Carcinoma
carrier who received her DNA test results at the age of 39 years and performed RRSO two 
years later at the age of 41 years. Before stopping OCS, the overall cumulative uptake 
of RRSO of all BRCA1/2 mutation carriers (before, at and beyond the recommended age 
range) within one year after receiving DNA test results was 53%. This is in agreement with 
the reported range of RRSO uptake that varies internationally between 34.9% and 73.5%24. 
After stopping OCS, the overall cumulative uptake of all BRCA1/2 mutation carriers within 
one year after DNA test result disclosure increased to 85%, which signifies a very high 
acceptance of RRSO as a risk management option in our total BRCA1/2 mutation carrier 
population. 
Furthermore, our findings suggest that stopping OCS was related to a shorter interval 
between DNA test result disclosure and RRSO. This association was found to be 
independent of the known associations with age and/or having children18–21. It is plausible 
that the increased uptake and more adequate timing of RRSO in period II is caused by 
the unequivocal advice by clinicians in favor of RRSO and the increased awareness of 
OCS ineffectiveness in our BRCA1/2 mutation carrier population. This is supported by 
a qualitative study that found that clinicians’ advice was a key factor in the decision to 
undergo RRSO and that awareness of OCS ineffectiveness was a secondary factor in this 
decision25. This was also previously suggested by others who indicated that worries about 
effectiveness of OCS was a factor in the decision for RRSO26,27. 
The reported data on the outcomes of the RRSO specimens is an extension of an earlier 
dataset used in a study concerning the histopathology of RRSO specimens at our family 
cancer clinic till March 201228. We report one additional occult cancer case. Our current 
study analyzed the percentage of occult cancers in BRCA1/2 mutation carriers before 
and after stopping OCS, which was 1.3% and 1.8% respectively. The percentages were 
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not statistically significantly different and remains low in our centre compared to other 
studies which reported occult cancer percentages from 2% to 12%5,29,30. 
In addition to stopping OCS, having reached the recommended age for RRSO and having 
two or more children were also related to a shorter interval between receiving DNA test 
results and RRSO. This is in agreement with four time-to-event studies that also found 
having children and/or age as related factors18–21. One study found an independent 
association between a personal history of breast cancer and a shorter time between 
receiving DNA test results and RRSO18, an association that we were unable to confirm. A 
possible explanation for the different outcome of this study could be that it was conducted 
in a population of high-risk women with only 26% proven BRCA1/2 mutation carriers18. 
The motivations for undergoing RRSO may differ in a non-proven high-risk population. 
Another time-to-event study in a population of proven BRCA1/2 mutation carriers also 
found no association between a personal history of breast cancer and a shorter time 
between receiving DNA test results and RRSO21. In agreement with our study, this study 
also found no association between a family history of breast and/or ovarian cancer and a 
shorter interval between receiving DNA test results and RRSO21.
To the best of our knowledge our study is the first to investigate the effect of stopping 
OCS on the timing and uptake of RRSO and outcomes of RRSO specimens in a large 
consecutive series of proven BRCA1/2 mutation carriers from one family cancer clinic. 
Furthermore, the majority of the data has been collected prospectively and our study has 
the longest follow-up period compared to other time-to-event studies.
Our study does not account for other possible changes in factors influencing the uptake 
and timing of RRSO. For example, a factor that could have influenced the timing of RRSO 
is the waiting time for surgery. However, the waiting time remained stable during the 
follow-up period of our study. The fact that our study is quantitative in nature is both a 
strength and a limitation, because qualitative information on patients’ underlying motives 
for RRSO is not included. 
When changing a clinical guideline it is important to establish its effect on clinical practice. 
Increasing the uptake of RRSO as soon as possible after receiving DNA test results is not an 
end in itself, however undergoing RRSO within the recommended age range is vital for its 
effectiveness in preventing BRCA1/2-mutation-related ovarian cancer12.  The way in which 
risk-management options were presented to women and the increased patient awareness 
of the ineffectiveness of OCS may have influenced the decision making process. It is a 
reassuring finding that after stopping OCS we did not find a deferral of surgery. Contrarily, a 
larger percentage of women chose to undergo RRSO within the recommended age range. 
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Part II
Psychological interventions alleviating menopausal symptoms after RRSO

The work described in this chapter was previously published in:
Maturitas 2018 May; 111:69-76
Chapter 5
Severity and duration of menopausal symptoms 
after risk-reducing salpingo-oophorectomy
Anniek Stuursma, 
Catheleine M.G. van Driel
Nienke J. Wessels,
 Geertruida H. de Bock
Marian J.E. Mourits
Introduction: To reduce the risk of ovarian cancer, women with BRCA1/2 mutations are 
advised to undergo risk-reducing salpingo-oophorectomy (RRSO) at premenopausal age. 
Premenopausal RRSO results in acute menopause and is associated with various menopausal 
symptoms. This study investigates the severity and duration of subjective menopausal 
symptoms after premenopausal RRSO and associated factors.
Methods: We included 199 women who underwent RRSO before age 52 in this cross-
sectional study. The Menopause Rating Scale (MRS) was used to measure the level of 
psychological, somato-vegetative and urogenital symptoms (no/little, mild, moderate, or 
severe). Uni– and multivariate logistic regression were performed to estimate odds ratios 
(ORs) and 95% confidence intervals (95% CIs) for having moderate or severe symptoms 
as compared to having no or mild symptoms. Duration of symptoms was investigated by 
calculating the time since RRSO. 
Results: Sixty-nine percent (137/199) of the included women reported moderate or severe 
symptoms on the MRS, 7.9 years (mean) after RRSO. Fifty-seven percent (94/137) of the 
women reported severe urogenital symptoms, and about one quarter reported severe 
psychological and/or somato-vegetative symptoms. Only psychological symptoms tended 
to improve over time (>=10 years). A personal history of breast cancer was independently 
associated with having moderate or severe menopausal symptoms (OR=3.4; 95%CI=1.6-7.1). 
Conclusion: The majority of women report moderate or severe menopausal symptoms, 
even 10 years after surgical menopause, in particular breast cancer survivors. To improve 
quality of life, follow-up care after RRSO should focus on these symptoms and be accessible 





Menopausal symptoms after RRSO
5
|   81 
Introduction 
The lifetime risk for women with a BRCA1 mutation to develop ovarian cancer by age 70 
has been estimated at 59% (95%CI = 43-76%) and for women with a BRCA2 mutation at 
16.5% (95%CI = 7.5-34%)1. These risks are considerably higher than the lifetime risk of 
1.4% in the general population2. In addition, the prognosis of ovarian cancer is poor, with 
a 5-year survival rate of 46.2%2. Ovarian screening is not effective in detecting cancer in 
an early and curable stage3, and at present risk-reducing salpingo-oophorectomy (RRSO) 
is considered the only effective option to reduce the risk of dying from ovarian cancer4. 
If performed within the recommended age ranges, RRSO can reduce ovarian cancer 
mortality with 95% and overall mortality with 76%5,6.
Women with a BRCA1 mutation are offered RRSO at the age of 35-40 years and those 
with a BRCA2 mutation at 40-45 years, provided child wish is fulfilled7. These age-ranges 
are ascertained from European and American guidelines and were identified as such 
because the incidence of ovarian cancer is expected to rise after those ages3,4. RRSO at 
premenopausal age will result in acute menopause and is likely to be associated with 
vasomotor and sexual symptoms, such as hot flashes, night sweats, vaginal dryness, loss 
of sexual interest and dyspareunia, which may lead to a decrease in quality of life8–11. 
Hormone replacement therapy (HRT) can alleviate the severity of menopausal symptoms, 
although it seems to have a modest effect on sexual symptoms and vasomotor symptom 
levels remain above a premenopausal level12. 
There is a large variety in reported severity and duration of menopausal symptoms, and 
literature on predictors are scarce, especially regarding surgical menopause13. The aim of 
this study was to evaluate the severity and duration of menopausal symptoms in women 
after premenopausal RRSO and to find factors associated with the severity and duration 
of these symptoms. With this knowledge, we aim to improve individual pre- and post-
surgery counselling regarding expected severity and duration of menopausal symptoms 
for women who opt for RRSO. Furthermore, to improve quality of life, we will be able 
to target additional interventions at women who are expected to experience severe 
menopausal symptoms after RRSO. 
Methods
Post-RRSO guidelines in the Netherlands 
In accordance with the Dutch national guideline, women in the Netherlands are offered 
RRSO without hysterectomy7. Hormone replacement therapy is prescribed to all women 
who are premenopausal at the time of RRSO, preferably tibolone, because this does not 
increase mammographic breast density. Women who have had a preventive mastectomy 
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are offered continuously combined hormone replacement therapy. If women suffer from 
vaginal symptoms, vaginal estriol is prescribed, which may be combined with tibolone 
in some occasions. For reducing hot flushes in breast cancer survivors, venlafaxine and 
clonidine are prescribed, which are moderately effective14, and vaginal estriol is prescribed 
to these women for vaginal symptoms7.
Study design and population
Women included in this cross-sectional study had undergone RRSO, for which they 
were counseled or treated in the UMCG15. These women were recruited in the baseline 
assessment of the PURSUE study (psychosexual consequences of risk reducing salpingo-
oophorectomy), a study investigating the effect of mindfulness-based stress reduction 
training on the experienced severity of menopausal symptoms [NCT02372864]. Women 
invited to participate in the PURSUE study had undergone RRSO and were younger than 52 
years at the time of RRSO. Women were excluded if they suffered from severe psychiatric 
illness or active cancer at the time of inclusion (current cancer treatment or diagnostic 
signs of cancer), if they had insufficient understanding of the Dutch language or if they 
were younger than 18 years. We did not exclude women with a history of breast cancer, 
nor did we exclude women using HRT or women who had undergone a hysterectomy.
For the PURSUE study, eligible women were sent an information letter, a purpose-designed 
screening questionnaire about the severity and frequency of menopausal symptoms and 
an informed consent form. Women were asked to return the questionnaire on menopausal 
symptoms, regardless of their willingness to participate in the randomized controlled 
PURSUE trial. All women who returned the PURSUE questionnaire on menopausal 
symptoms, were asked to participate in the current study. For the current study, an 
additional Menopausal Symptoms Study (MSS) questionnaire and consent form were 
sent. There was no advantage for women who returned the questionnaire, which reduced 
the influence of non-response bias. 
Recruitment for the current study took place from November 2015 until December 2016. 
A number of 239 women from the UMCG family cancer clinic returned the first PURSUE 
questionnaire and received the additional MSS questionnaire and consent form. Of those 
women, 200 returned the MSS questionnaire and 199 were included in the analyses of 
this study. A patient inclusion flow chart is presented in Figure 5.1. The Medical Ethical 
Committee of the University Medical Center Groningen accepted the protocol for the 
PURSUE study and the amendment to include the current study. Protection of the patients’ 
identity was guaranteed by assigning study-specific, unique patient numbers.
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Information on current age, date of RRSO, menopausal status at the time of RRSO, 
BRCA1/2 mutation status and breast cancer history was collected from the screening-
questionnaire of the PURSUE study. Menopausal status at the time of RRSO was asked 
because menopausal status could have changed due to breast cancer treatment. 
The additional MSS questionnaire contained questions regarding current length and 
weight, smoking/drinking habits, physical activity and the use of menopausal medication. 
Additionally, the Menopause Rating Scale (MRS) was included in the questionnaire to 
measure the level of menopausal symptoms, which has good reliability and validity, 
excellent applicability and sufficient repeatability16,17. 
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The MRS lists eleven symptoms that can be rated on a five-point Likert-type scale. The 
questionnaire consists of three subscales: psychological symptoms, somato-vegetative 
symptoms and urogenital symptoms. In the psychological subscale, depressive mood, 
irritability, anxiety and physical and mental exhaustion are rated. In the somato-vegetative 
subscale, hot flushes and sweating, heart discomfort, sleep problems and joint and 
muscular discomfort are rated. In the urogenital subscale, sexual problems, bladder 
problems and vaginal dryness are rated. Symptoms can be rated from 0 (no symptoms) 
to 4 (severe symptoms), leading to a maximum score of 44 points. The measured level 
of menopausal symptoms overall and the level of psychological, somato-vegetative 
and urogenital symptoms can be described as no/little, mild, moderate or severe. The 
allocation of scores per subscale is presented in Table 5.1.
Data on breast cancer treatment (chemotherapy, hormone therapy, radiotherapy and 
immunotherapy) was collected retrospectively from patient files. Data on duration of 
menopausal symptoms was analyzed by calculating time since RRSO.
Table 5.1: The symptom severity scores of the MRS: subscales and total 




Urogenital subscale  
(3 items)
MRS total  
(11 items) 
No, little 0-1 0-2 0 0-4
Mild 2-3 3-4 1 5-8
Moderate 4-6 5-8 2-3 9-16
Severe ≥7 ≥9 ≥4 ≥17
Maximum total 16 16 12 44
 
Statistical analysis
Characteristics were described for all women, and separately for women with no or mild 
symptoms (≤8 points on the MRS) and moderate or severe symptoms (≥9 points on the 
MRS)18. Being physically active was defined as exercising 5 days a week for 30 minutes 
or more, which is derived from the Dutch advice on physical activity and in line with 
international recommendations19,20. The questionnaire was generally well completed, 
with fewer than 0.5% missing data. Missing values were replaced by mean imputation. The 
highest percentage of missing data was 18% per questionnaire (2/11 questions) and 4.5% 
per question (9/199 questionnaires). To describe the duration of menopausal symptoms, 
the proportion of women reporting no/little, mild, moderate or severe symptoms was 
calculated at different time points after RRSO (0-1 year, 2-3 years, 4-5 years, 6-10 years and 
≥10 years). 
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Univariate logistic regression and multivariate logistic regression analyses were performed 
to identify factors associated with having moderate or severe symptoms as compared to 
having no or mild symptoms. Odds ratios (ORs) were calculated with 95% confidence 
intervals (95%CIs), with the severity of menopausal symptoms overall (no or mild versus 
moderate or severe symptoms) considered as the dependent variable. A sensitivity 
analysis was performed in which all current HRT-users were excluded from the analysis. All 
analyses were performed with IBM SPSS version 23 (IBM Corp., Armonk, NY, USA). P-values 
were considered significant if p < 0.05. 
Results 
Patient characteristics 
In Table 5.2 the patient characteristics are displayed. The mean age at the time of filling in 
the questionnaire was 50.5 years ± 6.7. A total of 68/199 (34.2%) women had a personal 
history of breast cancer. Eighty-one (40.7%) women had a history of HRT use and 48 
(24.5%) women were current HRT users at the time of filling in the questionnaire. 
Severity of menopausal symptoms per subscale
In Table 5.3 the level of menopausal symptoms is displayed per subscale. According to 
the MRS scores, 27 women (13.6%) experienced no/little symptoms, 35 (17.6%) mild 
symptoms, 76 (38.2%) moderate symptoms and 61 (30.7%) severe symptoms after a mean 
of 7.9 years ± 4.8 after RRSO (median 7.9 years, range 0.4-20.2). Severe symptoms were 
reported mostly in the urogenital domain, by 103 women (51.8%). 
Chapter 586   |
Table 5.2: Patient characteristics 
Characteristics All women Women reporting 









Number of women N = 199 N = 62 N= 137
Current age in years, mean (SD)
Age at time of RRSO in years, mean (SD)
Time since RRSO at time of MRS in years, mean (SD)
Mutation status, n (% of total)
    BRCA1
    BRCA2
    Unknown
Menopausal status at time of RRSO, n (% of total)
    Premenopausal 
    Postmenopausal
    Unknown
Ever HRT use, n (% of total)
Current HRT use, n (% of total)
Breast cancer history, n (% of total)
Time since last BC diagnosis, mean (SD) 
(n=68)
Breast cancer treatment, n (% of total) (n=68)
    Chemotherapy
    Radiotherapy
    Endocrine therapy
Body Mass Index, n (% of total)
    BMI ≤ 20
    BMI 20-25
    BMI ≥ 25  
Physical activity:  > 30 minutes a day active, n (% of total)
    0-4 days a week
    ≥ 5 days a week 
Alcohol consumption, n (% of total)
    0-6 glasses a week
    ≥ 7 glasses a week 
Smoking, n (% of total)
    No
    Yes
Hours of work outside the house per week, n (% of total)
    0
    1-23






















































































HRT: Hormone replacement therapy
MRS: Menopause rating scale
RRSO: Risk reducing salpingo-oophorectomy
* Numbers do not add up to the total number of women due to missing data
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Table 5.3: Frequency of menopausal symptoms per domain of the MRS (n=199)
Domain Frequency, % of total 
(n) (n=199)
Frequency of women with 
no or mild symptoms 
(n=62)
Frequency of women 
























Mild (2-3) 25.1 (50) 33.9 (21) 21.2 (29)
Moderate (4-6) 26.6 (53) 3.2 (2) 37.2 (51)
Severe (≥7) 21.1 (42) 0 (0) 30.7 (42)
Somato-vegetative domain
No, little (0-2) 20.1 (40) 51.6 (32) 5.8 (8)
Mild (3-4) 24.1 (48) 37.1 (23) 18.2 (25)
Moderate (5-8) 38.7 (77) 11.4 (7) 51.1 (70)
Severe (≥9) 17.1 (34) 0 (0) 24.8 (34)
Urogenital domain
No, little (0) 13.1 (26) 33.9 (21) 3.6 (5)
Mild (1) 11.1 (22) 21.0 (13) 6.6 (9)
Moderate (2-3) 24.1 (48) 30.6 (19) 21.2 (29)
Severe (≥4) 51.8 (103) 14.5 (9) 68.6 (94)
Duration and type of menopausal symptoms after RRSO 
In Figure 5.2 the distribution of symptom levels at different time points in different domains 
is displayed. Twenty-five women filled in the questionnaire 0-1 year after RRSO, 24 women 
2-3 years after RRSO, 29 women 4-5 years after RRSO, 56 women 6-10 years after RRSO and 
65 women ≥10 years after RRSO. Overall symptom severity levels and somato-vegetative 
symptom levels were reported at similar levels by women at different time points after 
RRSO. Sixty-four percent of the women who had undergone RRSO 0-1 year ago reported 
moderate or severe menopausal symptoms, of the women who had undergone RRSO ≥10 
years ago this was 66%. Psychological symptoms were reported more severe by women 
who had undergone RRSO more recently: 52% of the women who had undergone RRSO 
0-1 year ago reported moderate or severe symptoms, for the women who had undergone 
RRSO ≥10 this was 39%. Urogenital symptoms were reported more severe by women 
who had undergone RRSO longer ago: at 0-1 years after RRSO 84% reported moderate or 
severe symptoms, and at ≥10 years after RRSO this was 87%. 
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Figure 5.2: Severity of symptoms at different time points after RRSO in total and per 
subdomain, expressed as the percentage of all women per time point (n0-1year=25, n2-3years=24, 
n4-5years=29, n6-10years=56, n10+years=65)
a) The total score of the MRS (Severe symptoms: ≥17 points, Moderate symptoms: 9-16 points, Mild symptoms: 
5-8 points, No, little symptoms: 0-4 points). b) Psychological subscale (Severe symptoms: ≥7 points, Moderate 
symptoms: 4-6 points, Mild symptoms: 2-3 points, No, little symptoms: 0-1 point). c) Somato-vegetative 
subscale (Severe symptoms: ≥9 points, Moderate symptoms: 5-8 points, Mild symptoms: 3-4 points, No, little 
symptoms: 0-2 points). d) Urogenital subscale (Severe symptoms: ≥4 points, Moderate symptoms: 2-3 points, 

































































Uni- and multivariate logistic regression analyses of factors associated with mode-
rate or severe menopausal symptoms 
In Table 5.4 the univariate logistic regression analysis of factors associated with moderate 
or severe menopausal symptoms is displayed. In the univariate analysis, a personal 
history of breast cancer (OR = 3.8, 95% CI = 1.8-8.0) and having received breast cancer 
chemotherapy (OR = 2.8, 95% CI = 1.2-6.4) were statistically significantly associated with 
experiencing moderate or severe menopausal symptoms after RRSO. Current HRT-use was 
statistically significantly associated with experiencing no or mild menopausal symptoms 
(OR = 0.4, 95% CI = 0.2-0.8). When current HRT-users were excluded from the analysis, 
a personal history of breast cancer remained statistically significantly associated with 
moderate to severe symptoms after RRSO (OR = 3.0, 95% CI = 1.4-6.7). Chemotherapy was 
not statistically significantly associated with moderate or severe symptoms in this analysis. 
In the multivariate analysis, only a personal history of breast cancer was statistically 
significantly associated with experiencing moderate or severe menopausal symptoms 
after RRSO (OR = 3.4, 95% CI = 1.6-7.1, p = 0.001). 
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Table 5.4: Univariate logistic regression analysis of factors associated with the severity of 
menopausal symptoms after RRSO (n=199)
Variable Odds ratio, all women 
(n=199) (95% CI)
P-value Odds ratio, women 
using HRT excluded 
(n=118) (95% CI) 
P-value 
Time since RRSO
    ≤ 2 years
    2-5 years
    ≥ 5 years
Menopausal status at RRSO
   Premenopausal
   Postmenopausal
History of BC
    No
    Yes
BC chemotherapy
    No
    Yes
BC radiotherapy
    No
    Yes
HRT, current
    No
    Yes
Smoking, current
    No
    Yes
BMI 
    < 25
    ≥ 25
Alcohol consumption
    < 6 units per week
    ≥ 6 units per week
Physical activity, > 30 min. per 
day
    < 5 days per week
    ≥ 5 days per week
Time since last BC diagnosis 
(n=63)
          > 10 years





































































BMI: Body mass index 
HRT: Hormone replacement therapy 
RRSO: Risk reducing salpingo-oophorectomy
^ significant p-value
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Discussion 
This cross-sectional study including 199 women after RRSO at premenopausal age 
showed that a majority report moderate or severe menopausal symptoms, after a mean 
of 7.9 years after RRSO. A personal history of breast cancer was independently associated 
with moderate or severe menopausal symptoms after RRSO. 
Roughly half of the women reported severe urogenital symptoms, such as dysuria, vaginal 
dryness, itching, burning and dyspareunia, caused by chronic estrogen deprivation after 
menopause18. However, the proportion, severity and duration we observed after surgical 
menopause was much higher than has been observed in natural induced menopausal 
women21. In a study investigating the severity of symptoms in natural induced menopausal 
women, only 29.3% of the women reported urogenital symptoms, of which 40.8% 
rated it as a moderate and 11.2% as a severe problem22. A study investigating changes 
in severity of menopausal symptoms in natural induced menopausal women showed 
that vaginal symptoms increase with time. In this study, 4% of the early perimenopausal 
women experienced vaginal dryness, compared to 47% of the women three years after 
menopause23. 
Psychological symptoms tended to decrease with time, as women reported more severe 
symptoms directly after RRSO compared to ≥10 years after RRSO. This is in agreement 
with findings from longitudinal studies in natural menopausal women24,25. However, other 
authors did not find a decrease in psychological symptoms after (surgical) menopause, 
although they were unable to control for the effect of ageing26,27. The exact explanation for 
these differences in findings remains unclear, although it is suggested that psychological 
symptoms might not be related to changing estrogen levels, rather to ageing, health 
status and social factors28.
Hormone replacement therapy was not an independent determinant of severity of 
symptoms after RRSO in this study, which indicates that the symptom-reducing effect of 
HRT might be limited for some symptoms11. In a study by Tucker et al., no differences were 
found in rates of female sexual dysfunction and hypoactive sexual desire disorder between 
groups who did and who did not use HRT29. However, symptoms of dyspareunia and the 
overall severity of sexual symptoms could be improved with HRT. This corresponds with 
a study by Madalinska et al.11, in which women who used HRT reported the same level of 
sexual symptoms compared to women who did not use HRT, specifically symptoms of 
vaginal dryness and dyspareunia. 
In our study, an association was found between a history of breast cancer and the severity 
of menopausal symptoms after RRSO. Finch et al.9 could not find a significant difference 
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between breast cancer history and the level of vasomotor symptoms after surgery, 
although there was a significant difference in symptom levels before surgery. Nonetheless, 
women in their study were less likely to be sexually active before and after RRSO if they 
had a previous diagnosis of breast cancer. Therefore, it seems likely that a personal history 
of breast cancer may be associated with the overall severity of menopausal symptoms and 
the severity of sexual symptoms after RRSO, but that the level of vasomotor symptoms 
after RRSO may be unrelated to breast cancer history. 
We found a univariate association between breast cancer chemotherapy and the experience 
of moderate or severe menopausal symptoms after RRSO. Other studies have shown 
that chemotherapy and adjuvant endocrine therapy for breast cancer (LHRH analogues, 
tamoxifen, aromatase inhibitors) can cause or worsen menopausal symptoms30,31. Breast 
cancer chemotherapy may cause permanent or transient ovarian failure, dependent on 
age at treatment, dose and type of chemotherapy32. Additionally, adjuvant endocrine 
cancer therapy can cause or worsen menopausal and sexual symptoms as a side effect, 
although cessation of therapy leads to a reversal of complaints30. In the current study we 
excluded women who were currently treated for cancer, therefore, only long-term effects 
of past endocrine and chemotherapy use could be tested, which were not independently 
associated with severity of menopausal symptoms after RRSO. 
To the best of our knowledge, this is the first study to investigate the severity and 
duration of menopausal symptoms after premenopausal RRSO in different domains and 
at different time points with a follow-up and sample size this large. The main strenghts of 
this study are the widely used and validated questionnaire with a reliable scoring system 
for menopausal symptoms, the long-term follow-up and the high response rate of 83%.
A possible limitation of this study is that women who did not respond to the invitation for 
the PURSUE study, were not included in our sample. Women experiencing no or moderate 
symptoms might be less willing to fill in the questionnaire, which could have influenced 
our results. Another possible limitation of this study is that about 10% of the women 
included in our study were also included in the mindfulness arm of the PURSUE study, 
who had completed a mindfulness training before filling in the MSS. Therefore, the level of 
menopausal symptoms in our study might be underestimated. Another limitation is that 
causality and the development of symptoms over time cannot be established due to our 
cross-sectional design.
In conclusion, menopausal symptoms after surgical menopause by premenopausal RRSO 
are often moderate or severe and of long duration. Especially urogenital symptoms seem 
to be severe, and do not diminish over the years. Breast cancer survivors are at higher risk 
to experience moderate or severe menopausal symptoms after premenopausal RRSO. The 
results of this study indicate that follow-up care and interventions to alleviate menopausal 
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symptoms after RRSO should be accessible for more than 10 years after RRSO, particularly 
for breast cancer survivors. Further research is needed to investigate safe interventions 
targeted at women with severe menopausal symptoms who have a contraindication to 
use HRT.
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Mindfulness, cognitive-behavioral and behavioral-based therapy 
for natural and treatment-induced menopausal symptoms: 
a systematic review and meta-analysis
Catheleine M.G. van Driel, 
Anniek Stuursma, 
Maya J. Schroevers, 
Marian J.E. Mourits,
Geertruida H. de Bock
Introduction: During menopause women experience vasomotor and psychosexual 
symptoms that cannot entirely be alleviated with hormone replacement therapy (HRT). 
Besides, HRT is contraindicated after breast cancer. The aim was to review the evidence 
on the effectiveness of psychological interventions in reducing symptoms associated with 
menopause in natural or treatment-induced menopausal women. 
Methods: Medline/Pubmed, PsycINFO, EMBASE and AMED were searched until June, 2017. 
Randomized controlled trials (RCTs) concerning natural or treatment-induced menopause, 
investigating mindfulness or (cognitive-)behavioral-based therapy were selected. Main 
outcomes were frequency of hot flushes, experienced bother by hot flushes, other 
menopausal symptoms and sexual functioning. Study selection and data extraction were 
performed by two independent researchers. A meta-analysis was done to calculate the 
standardized mean difference (SMD).
Results: Twelve RCTs were included. Short-term (<20wk) effects of psychological 
interventions in comparison to no treatment or control were observed for hot flush bother 
(SMD: -0.54, 95%CI: -0.74 to -0.35, p<0.001, I2=18%) and menopausal symptoms (SMD: -0.34, 
95%CI: -0.52 to -0.15, p<0.001, I2=0%). Medium-term (≥20wk) effects were observed for hot 
flush bother (SMD: -0.38, 95%CI: -0.58 to -0.18, p<0.001, I2=16%). In the subgroup treatment-
induced menopause, consisting of exclusively breast cancer populations, as well as in the 
subgroup natural menopause hot flush bother was reduced by psychological interventions. 
Too few studies reported on sexual functioning to perform a meta-analysis.
Conclusion: Psychological interventions reduced hot flush bother on the short and 
medium-term and menopausal symptoms on the short-term. These results are especially 
relevant for breast cancer survivors in whom HRT is contraindicated. There was a lack of 
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Introduction 
Menopause can occur either naturally or can be induced by treatments such as pelvic 
radiation, oophorectomy, endocrine therapy or chemotherapy1,2. Menopausal symptoms 
are experienced frequently with up to 85% of menopausal women reporting vasomotor 
symptoms (i.e. hot flushes and night sweats), up to 60% reporting vaginal discomfort (i.e. 
vaginal dryness and/or dyspareunia), and up to 87% reporting sexual dysfunction (e.g. 
lack of sexual desire and difficulty reaching orgasm)3–5. Moreover, women who experience 
treatment-induced menopause report more severe symptom levels than women 
experiencing natural menopause6,7. 
To reduce the aforementioned symptoms, hormone replacement therapy (HRT) is 
currently the most effective option8,9. However, the use of HRT in postmenopausal women 
is associated with increased breast cancer risk and contraindicated in breast cancer 
survivors10,11. Furthermore, HRT only partially relieves symptoms, symptom levels remain 
higher than in premenopausal women and especially sexual discomfort is not alleviated12. 
Therefore, safe non-hormonal alternatives to HRT are needed, in particular for breast 
cancer survivors such as young BRCA1/2 mutation carriers after breast cancer and risk-
reducing salpingo-oophorectomy. 
Non-hormonal options to decrease the frequency and bother of hot flushes include 
stress-reducing psychological interventions such as cognitive behavioral therapy 
(CBT), behavioral therapy (BT) and mindfulness-based therapies (MBT)13. The possible 
mechanism of action of these interventions is that they reduce stress. Stress is thought 
to lower the threshold for heat dissipation responses14,15 and therefore can potentiate a 
hot flush16. It is proposed that CBT, BT and MBT diminish this trigger by reducing stress, 
thus reducing the frequency of hot flushes. An additional mechanism of action of the 
abovementioned interventions might be that by modifying cognitive appraisals of hot 
flushes, the bother caused by hot flushes can be decreased13. 
Several large randomized controlled trials that were recently published have investigated 
the effect of CBT, MBT and BT on hot flushes and other menopausal symptoms17–20. The 
aim of this systematic review and meta-analysis is to add a quantitative examination of 
the existing evidence on the effectiveness of psychological interventions in reducing 
symptoms associated with menopause in natural or treatment-induced menopausal 
women.
Chapter 6100   |
Methods 
The conduct and reporting of this systematic literature review and meta-analysis was 
based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) statement21. Firstly, studies were screened for eligibility based on their titles 
and abstract. Full texts of possibly eligible studies were retrieved after the initial screening 
for more detailed evaluation. Secondly, two review authors (CD and AS) independently 
performed a final selection of studies, assessed the risk of bias and extracted data from the 
full-text papers using a pre-specified form. The following data was extracted with the use 
of these forms: population (e.g. sample size, natural or treatment-induced menopause), 
intervention (e.g. type of intervention, duration, length of program), control group, co-
interventions and outcomes (e.g. frequency and bother of hot flushes, menopausal 
symptoms, sexual functioning and adverse effects). Of the outcomes the time points of 
measurement and results such as means and measure of variance were extracted.
Menopausal symptoms were defined as the combined level of burden by a broad range 
of symptoms related to menopause such as psychosocial symptoms (e.g. irritability, 
forgetfulness), physical symptoms (e.g. joint pain, headaches), genital symptoms (e.g. 
dryness, itching), sexual dysfunction and vasomotor symptoms. 
Electronic databases that were searched are Medline/Pubmed, EMBASE, PsycINFO and 
AMED. Other search methods used were reference checking of selected studies and of 
existing reviews on adjacent topics. The initial search was conducted in February 2016 and 
an updated search was performed in June 2017. 
Risk of bias was assessed with the risk of bias tool from the Cochrane collaboration22. 
Disagreements on inclusion of studies, extracted data or risk of bias assessments was solved 
by consensus between the two review authors (CD and AS). If consensus was not reached 
the other authors were consulted (GB, MS & MM). The protocol of this systematic literature 
review and meta-analysis is registered in the PROSPERO database (CRD42016038135).
Eligibility criteria
Studies considered eligible were RCTs with a published full-text in English evaluating the 
effect of CBT, BT or MBT on either naturally occurring or treatment-induced hot flushes, 
menopausal symptoms or sexual functioning as compared to a waiting list or to “care 
as usual” (e.g. lifestyle advice, breast cancer follow-up). Menopause did not have to be 
formally established (e.g. by amenorrhea > 12 months or laboratory tests), but could be 
based on patient-reported signs and symptoms of menopause. The intervention could 
either consist of group or individual therapy and could be a general program or could 
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be specifically tailored to symptoms associated with menopause. Only patient-reported 
outcomes were included.
Studies were excluded if interventions were limited to yoga, hypnosis, exercise, meditation, 
awareness training or breathing techniques as a stand-alone therapy, because these 
interventions were either not based on a stress-reducing mechanism of action or were 
not based on widely used protocolled standards. Studies were also excluded if there 
was no face-to-face therapeutic contact with a therapist or trainer during the study 
(e.g web-based interventions). Use of HRT in the intervention and/or control group was 
allowed. However, studies that specifically aimed to use HRT as the control condition 
were excluded. Lastly, studies were excluded if the outcomes were physical measures (e.g. 
sternal skin conductance) only. The rationale behind favoring patient-reported outcomes 
over physical measures was that patient-reported hot flush frequency could be more 
closely related to actual inconvenience caused by hot flushes as patient-reported hot 
flush frequency measures the perceptual aspect, whereas physical measures assess the 
physiological aspect of the hot flush construct23. Therefore we deemed patient-reported 
outcomes of more interest for clinical practice.
Statistical analysis
The following outcomes were considered at short-term (<20 weeks post randomization) 
and at medium-term (≥20 weeks post randomization): frequency and bother of hot flushes, 
menopausal symptoms and sexual functioning. A random effects meta-analysis using 
inverse variance method was performed. Using mean endpoints and standard deviations 
(SDs), per study a standardized mean difference (SMD) with a 95% confidence interval (CI) 
was calculated for all outcomes.  Effect sizes were defined as small (0.2); medium (0.5) or 
large (0.8)24. Heterogeneity was assessed per outcome with I2, χ2 and p-value. Funnel plots 
were made to assess publication bias. Asymmetrical funnel plots indicate a higher risk 
of publication bias22. Asymmetry was assessed using Egger’s test which was interpreted 
using a cut-off value of 0.1025. As the effect of the interventions could differ for treatment-
induced and natural menopausal symptoms, a subgroup analysis was performed for 
natural menopause versus treatment-induced menopause when two or more studies 
were available per subgroup for an outcome. All analyses were performed using Review 
manager (RevMan version 5.3.5.).
Results  
Selection of studies 
A flow diagram of the study selection is shown in Figure 6.1. Based on the title and abstract 
screening, 24 records were eligible for full-text assessment of which twelve records did 
not meet the eligibility criteria. So, the final number of included studies in the qualitative 
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Figure 6.1: Flow diagram of study selection
synthesis was twelve. Of the included studies, ten studies could be included in the main 
quantitative synthesis (meta-analysis), as two studies only reported medians because of 
possible skewness of the data26,27. An overview of studies reporting medians compared to 
studies in the main meta-analysis is shown in Figure 6.2.
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Figure 6.2: Forrest plot of hot flush frequency, hot flush bother, menopausal symptoms and 
sexual functioning for both short-term (<20 wk) and medium-term (≥20 wk) results, split for 
mean and median outcomes.
Figure 2: Forrest plot o  hot ﬂush frequency, hot ﬂush bother, menopausal sy ptoms and sexua  func�oning 
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Characteristics of included studies 
The total size of study population per study varied from 16 to 214 women (Table 6.1). 
The combined sample size of all studies consisting of participants in the control and 
intervention groups was 1,016 women. Six of the twelve included studies involved 
women whose symptoms were treatment-induced, all of which concerned breast 
cancer survivors17,19,26–29. Three studies investigated the effect of MBT19,28,30, five studies 
investigated CBT17,18,29,31,32 and four studies investigated BT20,26,27,33. All studies, except three 
had a waiting list control group27,29,33. One study had a “care as usual” control group29 which 
consisted of breast cancer survivors during follow up with lifestyle advice on coping 
with hot flushes by a nurse specialist. The second study had a population of women 
experiencing natural menopause and had an active control group. The placebo activity 
in this case was individual leisure reading33. The third study was conducted in breast 
cancer survivors and had an attention control group. The attention consisted of a general 
discussion of menopausal complaints with a nurse27. 
To measure hot flush frequency, the frequency subscale of the hot flush rating scale 
(HFRS scale) or similar diaries were used. Hot flush bother was most often measured by 
the HFRS subscale that measures bother by hot flushes (problem-rating, distress and 
interference). Menopausal symptoms were measured using the Functional Assessment 
of Cancer Therapy – Endocrine Therapy Scale (FACT-ES) and the Menopausal Quality of 
life scale (MENQOL). Both questionnaires contain psychosocial, physical, vaginal, sexual 
and vasomotor related items. Sexual activity was measured by the habit subscale of the 
Sexual Activity Questionnaire (SAQ) and sexual behavior subscale of the Women’s Health 
Questionnaire (WHQ). 
Assessment of risk of bias 
A high risk of performance bias was present for all studies, because blinding of CBT, BT and 
MBT-based interventions is not feasible. Consequently, the risk of detection bias was high 
as outcomes were patient-reported. 
Meta-analysis of overall effect 
A statistically significant benefit from psychological interventions was seen on short-term 
hot flush bother (SMD: -0.54, 95% CI: -0.74 to -0.35, p<0.001), short-term menopausal 
symptoms (SMD: -0.34, 95% CI: -0.52 to -0.15, p<0.001) and medium-term hot flush 
bother (SMD: -0.38, 95% CI: -0.58 to -0.18, p<0.001) (Table 6.2). No statistically significant 
benefit from psychological interventions was seen on short-term hot flush frequency 
(SMD: -0.41, 95% CI: -0.83 to 0.01, p=0.05) or medium-term hot flush frequency (SMD: 
-0.21, 95% CI: -0.89 to 0.26, p=0.29). Heterogeneity was high for most outcomes. A meta-
analysis of sexual functioning was not feasible because only two studies reported on this 
outcome17,20.
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Table 6.2: Meta-analysis for hot flush frequency, hot flush bother and menopausal symptoms 
(short and medium-term)
Outcome Number of 
studies 
N total SMD (95%CI) P (overall effect) I2#/X2/P (heterogeneity)
Short-term (<20wks)
HF frequency 6 300 -0.41 [-0.83,  0.01] 0.05 65%/14.19/0.01
HF bother 7 568 -0.63 [-0.80, -0.46] <0.001* 0%/6.49/0.48
Menopausal symptoms 3 474 -0.34 [-0.52, -0.15] <0.001* 0%/1.46/0.48
Medium-term (≥20wks)
HF frequency 3 234 -0.31 [-0.89,  0.26] 0.29 79%/9.55/0.008
HF bother 5 486 -0.49 [-0.80, -0.19] 0.002* 63%/10.75/0.03
Menopausal symptoms 2 264 -0.45 [-1.07, 0.18] 0.16 83%/5.82/0.02
SDM: standardized mean, HF: hot flushes, wks: weeks.
* statistically significant (<0.05%)
# low: 0-24%, moderate: 25-49%, substantial: 50-74%, significant 75-100%22.
Publication bias 
The Egger test result was >0.10 for all studies indicating no proof of statistically significant 
publication bias. However the funnel plots showed some asymmetry, indicating that this 
result could be due to a limited number of studies per outcome (data not shown).
Subgroup analysis 
A beneficial effect of psychological interventions was seen on short-term hot flush bother 
in the subgroup treatment-induced menopause (SMD: -0.47, 95% CI: -0.69 to -0.25, 
p<0.001) as well as in the subgroup natural menopause (SMD: -0.85, 95% CI: -1.11 to -0.59, 
p<0.001). Benefit of psychological interventions was also seen on medium-term hot flush 
bother for both the natural menopause subgroup (SMD: -0.77, 95% CI: -1.16 to -0.39, 
p<0.001) as well as in the treatment-induced menopause subgroup (SMD: -0.32, 95% CI: 
-0.64 to 0.00, p=0.05). 
Adverse effects




A small to moderate reduction of short- and medium-term hot flush bother and short-
term menopausal symptoms by psychological interventions (i.e. CBT, BT and MBT) was 
found in the meta-analysis. Hot flush frequency however, was not statistically significantly 
reduced by psychological interventions. Furthermore, the short and medium term hot 
flush bother was reduced by psychological interventions in the breast cancer survivor 
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subgroup and the natural menopause subgroup. However, medium term hot flush bother 
reduction was bordering on statistical significance in the breast cancer survivor subgroup. 
No adverse effects caused by psychological interventions were reported. 
Strengths and limitations 
This systematic literature review and meta-analysis is the first to investigate and quantify 
the efficacy of CBT, BT and MBT on menopausal symptoms in both naturally occurring 
and treatment-induced menopause in survivors of breast cancer with inclusion of recently 
published studies and novel mindfulness interventions. Furthermore, a large number of 
RCTs were included and subgroup analyses were possible for natural and treatment-
induced subgroups for most outcomes. An important aspect of this systematic literature 
review and meta-analysis is that only patient-reported outcomes were included, which 
reflect the actual inconvenience caused by hot flushes23. A high level of heterogeneity 
was found in the meta-analysis, likely because of the differences in populations (natural 
vs. treatment-induced) and possibly due to differences between interventions (e.g. type, 
duration). The level of heterogeneity was not of great concern because the aim of this 
systematic literature review and meta-analysis was to answer the wider question about 
the effectiveness of psychological interventions as a whole, as they are all based on 
the similar principal of stressor impact reduction, in all menopausal women regardless 
of cause. Other limitations were the fact that some of the included RCTs were small (i.e. 
five of the twelve studies consisted of <60 participants in total) and possible presence of 
publication bias.  
Interpretation
Hot flush bother versus hot flush frequency
As reduction of hot flush bother was greater than the reduction of hot flush frequency it 
could be that the main mechanism of action of psychological interventions is to modify 
cognitive appraisal of hot flushes, thereby increasing coping skills to reduce the impact of 
hot flushes13. In the general population, women who report a low frequency of hot flushes 
can still experience substantial bother by hot flushes and vice versa34. Frequency of hot 
flushes has been identified as being associated with bother by hot flushes34. However, they 
were not interchangeable as other factors such as affect, symptom sensitivity, general 
health, and sleep problems are also associated with the level of bother by hot flushes34. So, 
reduction of bother by hot flushes might be the most appropriate measure of improved 
quality of life in women suffering from vasomotor symptoms34,35.
Effectiveness in breast cancer survivors 
Psychological interventions could be a valid strategy to reduce hot flush bother in breast 
cancer survivors. This is an important finding of the meta-analysis as breast cancer 
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survivors are contraindicated to use HRT, but report more frequent, more severe, more 
distressing and a longer duration of hot flushes compared to age-matched controls or 
naturally menopausal women6,36–38. 
Lack of long-term outcomes 
No studies reported on long-term (≥ 52 weeks) outcomes. The effect of a booster session 
on maintaining the effect of the intervention warrants further investigation. This could 
not be evaluated properly in the meta-analysis because only two studies incorporated a 
booster session and did so within the short-term period17,27. 
Lack of sexual outcomes
Only two of the 12 included studies reported on sexual outcomes17,20. The lack of sexual 
outcomes in current research stands in stark contrast to the fact that sexual functioning 
is shown to be severely impaired during menopause with 76% of menopausal 
women reporting sexual dysfunction5,39–41. A recent one-armed pilot study aimed at 
improving sexual functioning in surgical menopausal women investigated the effect 
of an intervention combining MBT and sexual health education and found statistically 
significant improvement of sexual functioning42. This suggests that psychological therapy 
could be an effective intervention to improving sexual functioning in menopause. Indeed, 
a review by Al-Azzawi et al., concludes that non-pharmacological approaches, including 
psychological therapy, should be the first step in treating postmenopausal sexual 
dysfunction, before moving on to pharmacological options43. 
Other causes of treatment-induced menopause
Lastly, breast cancer treatment was the only cause for treatment-induced menopause that 
was investigated in the included studies. However, there are more causes for treatment-
induced menopause such as risk-reducing salpingo-oophorectomy in women with 
high risk for ovarian cancer (e.g. BRCA1/2 mutation carriers). Risk-reducing salpingo-
oophorectomy in BRCA1/2 mutation carriers has become a widely applied procedure 
causing early surgical menopause44–47. Next to an increased risk for developing ovarian 
cancer, BRCA1/2 mutation carriers also have an increased risk to develop breast cancer48–52. 
About one third of BRCA1/2 mutation carriers who experience surgical menopause have 
had breast cancer and therefore have a contraindication for using HRT53. This signifies the 
need for a safe, non-hormonal alternative for alleviating menopausal symptoms in groups 
with different causes of treatment-induced menopause. 
Conclusion
The need for non-hormonal alternatives to HRT has been firmly established following 
the publication of the Women’s Health Initiative10 and considering the contra-indication 
of HRT in breast cancer survivors. The results of this review suggest that psychological 
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interventions could be a safe and effective treatment that reduce bother by hot flushes 
in all women experiencing symptoms associated with menopause, including breast 
cancer survivors. These findings support healthcare providers in offering psychological 
interventions to women who suffer from hot flushes and menopausal complaints, 
especially for women who will not be using HRT. 
However, larger trials with a longer follow-up time are needed to confirm the (long-term) 
effectiveness of psychological therapies. Furthermore, RCTs investigating the comparative 
effectiveness of CBT, BT, and MBT are needed, as studies on this topic are scarce.
The staggering lack of sexual outcomes in current research in conjunction with the fact 
that sexual functioning is severely impacted during menopause, emphasizes that future 
research should focus on the effect of psychological interventions on sexual outcomes. 
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Chapter 7
Mindfulness-based stress reduction for menopausal symptoms  
after risk-reducing salpingo-oophorectomy (PURSUE study):
a randomized controlled trial
Catheleine M.G. van Driel, 
Geertruida H. de Bock, 
Maya J. Schroevers, 
Marian J.E. Mourits
Introduction: The aim of this study was to assess the short- and long-term effects of 
mindfulness-based stress reduction (MBSR) on the resulting quality of life, sexual functioning, 
and sexual distress after risk-reducing salpingo-oophorectomy (RRSO).
Methods: A randomized controlled trial was performed in a specialized family cancer clinic 
of the university medical center Groningen. 66 women carriers of the BRCA1/2 mutation 
who developed at least two moderate-to-severe menopausal symptoms after RRSO were 
included. Women were randomized to an 8 week MBSR training or care as usual (CAU). 
The man outcome measures were the change in the Menopause-Specific Quality of Life 
Questionnaire (MENQOL), the Female Sexual Function Index, and the Female Sexual Distress 
Scale administered from baseline at 3, 6, and 12 months. Linear mixed modeling was applied 
to compare the effect of MBSR with CAU over time.
Results: At 3 and 12 months there were statistically significant improvements in the MENQOL 
for the MBSR group compared with the CAU group (both p = 0.04). At 3 months, the mean 
MENQOL scores were 3.5 (95% confidence interval [95%CI], 3.0–3.9) and 3.8 (95%CI, 3.3–4.2) 
for the MBSR and CAU groups, respectively; at 12 months, the corresponding values were 3.6 
(95%CI, 3.1–4.0) and 3.9 (95%CI, 3.5–4.4). No significant differences were found between the 
MBSR and CAU groups in the other scores.
Conclusion: MBSR was effective at improving quality of life in the short- and long-term 
for patients with menopausal symptoms after RRSO. However, it was not associated with 
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Introduction
Women carrying a BRCA1 or BRCA2 mutation have an increased lifetime risk of developing 
breast and ovarian cancer compared with the general population1–4. At present, because 
ovarian cancer screening is ineffective for early detection, offering risk-reducing salpingo-
oophorectomy (RRSO) is standard practice to reduce the incidence of ovarian cancer in 
these women5–8. RRSO is recommended at the ages of 35 to 40 years for BRCA1 mutation 
carriers and at 40 to 45 years for BRCA2 mutation carriers, provided there is no desire to 
have more children9–13. There is good evidence that the procedure reduces the risk of 
ovarian cancer by up to 96% when performed within these age ranges14–17.
The acute surgical menopause induced by RRSO is associated with sequelae, of which hot 
flashes, (night) sweats, vaginal dryness, loss of sexual desire, and pain during intercourse 
are the most frequent18–27. Moreover, it is reported that menopausal symptoms are more 
severe after acute surgical menopause than after natural menopause28. Although hormone 
replacement therapy (HRT) can alleviate the symptoms, they only do so partially, and 
symptom levels remain above those of premenopausal women22. Confounding this issue 
is the fact that one-third of BRCA1/2 mutation carriers who undergo RRSO have had breast 
cancer, contraindicating HRT use29,30. Therefore, non-hormonal methods are needed to 
alleviate menopausal symptoms induced by RRSO in breast cancer survivors.
A possible non-hormonal alternative could be a psychological intervention that targets 
perception and acceptance, such as mindfulness-based training. The goal of such training 
is to help the patient pay full attention to the present moment in a non-judgmental, 
accepting way31. Specifically, the mindfulness-based stress reduction (MBSR) method 
achieve this through a well-described, protocol-based training program over an eight-
week period. The program consists of meditation, gentle yoga poses, and body awareness 
exercises. In studies carried out in women experiencing menopausal symptoms after 
breast cancer treatment or natural menopause, MBSR has shown promise for both 
reducing difficulty with hot flushes and improving menopause-specific quality of life32–35. 
However, these studies were not carried out in women with RRSO-induced menopause, 
and they were either uncontrolled or had short follow-up periods.
In the present study, we aimed to investigate the short- and long-term effects of MBSR 
compared to care as usual (CAU) in BRCA1/2 mutation carriers after RRSO. Specifically, we 
were interested in the effects on menopause-specific quality of life (primary outcome) 
and on sexual functioning and sexual distress (secondary outcomes).
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Methods
Study Design
The randomized controlled trial, “Psychosexual conseqUences of Risk-reducing Salpingo-
oophorectomy in BRCA1/2 mUtation carriErs” (PURSUE) study is an open label trial and was 
approved by the Medical Ethical Committee of the University Medical Center Groningen 
on November 14, 2014 (registration number NL46796.042.14). It was conducted in 
accordance with the principles of the Declaration of Helsinki (as amended in 2013) and 
the relevant Dutch legislation (the Medical Research Involving Human Subjects Act). 
The ClinicalTrials.gov Identifier for the trial is NCT02372864. Women were recruited for 
participation from January 2015 to October 2015, and were followed for one year after 
randomization. Patients were not involved in the development of the study.
Participants
The clinical data for women referred to the Family Cancer Clinic of the University Medical 
Center Groningen at increased risk of developing breast or ovarian cancer, including 
BRCA1/2 mutation carriers, have been prospectively recorded in a database since 199436. 
We contacted BRCA1/2 mutation carriers who underwent RRSO at an age younger than 
52 years by letter detailing the possibility of receiving MBSR training aimed at alleviating 
menopausal symptoms after RRSO. The letter included a purpose-designed questionnaire 
(see Appendix S1) about the presence and severity of menopausal symptoms. Cancer 
history and current psychiatric and cancer treatment were recorded on the questionnaire. 
Women were eligible for participation if they had undergone RRSO before the age of 
52 years and reported at least two moderate-to-severe menopausal symptoms in the 
two preceding weeks. We excluded the following groups: those who were undergoing 
cancer treatment at the time of inclusion, apart from those receiving adjuvant hormonal 
or immune therapy; those who were receiving psychiatric care; and those who had 
insufficient understanding of the Dutch language to complete questionnaires. We did 
not exclude women using HRT, non-hormonal medications (e.g. clonidine), or dietary 
or herbal remedies (e.g. soy, black cohosh), or those with a history of breast cancer. All 
eligible women were invited for an intake visit, and after giving written informed consent, 
were randomized to an intervention or a control group. The intervention group received 
an eight-week MBSR training course, plus CAU, whereas the control group received only 
CAU.
Interventions
Participants in the MBSR group received an eight-week MBSR training course (Appendix 
S2). This comprised weekly sessions lasting two and half hours each, a silent retreat evening 
lasting four hours, and a commitment to performing mindfulness exercises at home for 
30–45 minutes on six days of the week using instructions on a provided MP3 player31. The 
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MBSR training was a standard training program and not specifically adapted to focus on 
menopausal symptoms. In total, six MBSR training classes were organized, each with four 
to seven study participants only. Training classes took place at three locations in the north 
of the Netherlands to reduce travel time for participants, and all were led by one of three 
certified and experienced MBSR trainers.
Care as Usual
CAU consisted of information provided by a specialist nurse during the intake visit. This 
covered lifestyle advice for hot flashes, night sweats, vaginal dryness, sexual functioning, 
cardiovascular health, and bone health. An information booklet summarizing this 
information was provided to participants in both groups. Approximately 12 weeks after 
randomization, all participants were offered a repeat appointment with the nurse to 
address any remaining issues.
Randomization
We used block randomization stratified by HRT use. Randomization was done by the 
independent trial coordination center of the University Medical Center Groningen via a 
web-application, using a computerized random number generator. After randomization, 
an e-mail was automatically sent to the research nurse and researchers detailing the group 
allocation of that particular study participant. The participants were informed about their 
allocation group by the research nurse.
Assessments
Questionnaires were sent by mail at randomization (T0, baseline), and at three (T1), six (T2) 
and twelve (T3) months thereafter. If participants did not respond, a second request was 
sent after four weeks and a third request after eight weeks. If no response was received 
after twelve weeks, or the data was unclear, the participant was contacted by e-mail and/
or phone by a researcher.
Baseline Descriptive Measures
The following baseline characteristics were collected: age, weight, height, marital or 
cohabitating status, parity, number of children living at home, highest completed 
education, employment, smoking history, alcohol consumption, exercise behavior, breast 
cancer history, mastectomy history, and HRT use. In addition, anxiety and depression were 
screened for using the Generalized Anxiety Disorder 7 (GAD-7) questionnaire37 and the 
Patient Health Questionnaire-2 (PHQ-2)38, respectively.
Primary Outcome Measure
The primary outcome of interest was menopause-specific quality of life, as measured by 
the Menopause-specific Quality of Life questionnaire (MENQOL). The MENQOL is a self-
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administered 29-item questionnaire that assesses quality of life in menopausal women 
over the preceding four weeks39. It records the presence and the severity of menopausal 
symptoms as the degree of perceived burden (or bother) women experience from 
menopausal symptoms, using seven-point scales per item. It consists of four domains: 
vasomotor (three items), psychosocial (seven items), physical (16 items), and sexual (three 
items). The domain scores range from one to eight, with one reflecting an absence of 
symptoms and eight reflecting extremely bothersome symptoms. A cut-off score is not 
available.
Secondary Outcome Measures
The Female Sexual Function Index questionnaire (FSFI) consists of 19 items on six sub-
domains: desire, arousal, lubrication, orgasm, satisfaction, and pain40. Each domain 
is scored on a Likert-type scale from zero to five. Higher scores indicate better sexual 
functioning in the prior four weeks, and a score <26.55 indicates sexual dysfunction41.
Sexual distress was determined using the Female Sexual Distress Scale questionnaire 
(FSDS) for the preceding four weeks. The FSDS consists of 12 items scored on a five-point 
Likert scale from zero (no distress) to four (always experiencing distress)42. A score of 11 or 
higher indicates sexual distress43.
Sample Size Calculation
The minimum sample size was calculated as 64 with and 60 without correcting for 
10% attrition based on a minimal clinically relevant difference of 1.0 on the MENQOL, a 
standard deviation of 1.36 based on a previous RCT that compared the change in MENQOL 
score between a MBSR intervention group and a waiting list control group at 20 weeks in 
naturally post and perimenopausal women33, a statistical power of 80% and an α of 0.0533. 
Quality Control
To improve consistency and uniformity of the MBSR training sessions, three meetings were 
organized with the trainers under the supervision of an experienced MBSR trainer (MS), 
and adherence to the protocol was assessed by audio recordings of 6/48 (12.5%) of all 
training sessions. Protocol adherence was defined as the weighted average of agreement 
between the specified and actual exercise duration. Participant attendance was recorded 
by trainers at start of each session, and participants were asked to report the frequency 
and duration of daily home exercises on weekly evaluation forms during the intervention 
period.
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Statistical Analysis
In case of missing items in the questionnaires, scores were calculated using mean 
imputation if at least 80% of the answers had been given. Baseline characteristics were 
described for each treatment arm using means and standard deviations for continuous 
variables and using frequencies for categorical variables. The primary and secondary 
outcomes were analyzed by linear mixed modeling to allow for the inclusion of women 
with missing time points for longitudinal data. The scores on the MENQOL, FSDS, FSFI, and 
their sub-domains at T0, T1, T2, and T3 were modeled as a function of the treatment arm, 
the time moment, and the interaction between the treatment arm and the time moment. 
An unstructured data matrix was assumed because the data did not indicate another 
correlation structure. All analyses were performed on an intention-to-treat basis. The 
normality of the outcome measures was determined by visual inspection of a Q-Q plot.
We used IBM SPSS version 23 (IBM Corp., Armonk, NY, USA) for all analyses. All p-values 
were two-tailed and considered significant if p < 0.05.
Funding
The C&W de Boer Foundation provided funding for the research. The funding source had 
no role in the study design, collection, analysis, or interpretation of data, or in the writing 
of the manuscript or in the decision to submit it for publication. The corresponding author 




Of the 365 women informed about the study, 218 women completed and returned the 
questionnaires on the presence and severity of menopausal symptoms (Figure 7.1); of 
these, 197 met the inclusion criteria and 66 agreed to participate and be randomized 
to the MBSR (n = 34) and CAU (n = 32) groups. One participant in the CAU group did 
not return the questionnaire at T0 or at subsequent time points for unknown reasons, 
so baseline data were available for 65 participants (34 MBSR, 31 CAU). At inclusion, the 
average age of the participants was 47.7 ± 5.2 years, and 19 out of 65 (29%) women used 
HRT (Table 7.1). Furthermore, 17 out of 65 women (26%) had a history of breast cancer.
Six participants did not complete the intervention, with two citing scheduling conflicts, 
two citing that it was too time consuming, and two citing that they were not expecting a 
benefit. At each time point, at least 70% of participants returned their questionnaires, and 
the reasons for non-response are shown in Figure 7.1. In total, 53 women completed the 
MENQOL questionnaire at T1 resulting in a statistical power of 76%.
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T0, zero months# (n=34) 
Contacted and asked to complete questionnaire (n=365) 
Randomized (n=66) 
MBSR group (n=34) 
- Did not respond/complete questionnaire* (n=147) 
- Did respond (n=218) 
 - Did not meet inclusion criteria (n=21) 
  - <2 moderate to severe symptoms (n=16) 
  - Undergoing cancer treatment (n=1) 
  - Severe psychiatric problems (n=4) 
 - Met inclusion criteria (n=197) 
  - Not interested in participation (n=132) 













T1, three months# (n=28) 
-  
T2, six months# (n=24) 
2 drop-outs; reasons: 
- Questionnaires were burdensome (1) 
- Unknown (1) 
2 did not respond, reasons: 
- Unknown (2) 
CAU group (n=32) 
T3, 12 months# (n=23)  
3 did not respond; reasons: 
- Unknown (3) 
 
T0, zero months# (n=31)  
1 drop-out; reason: 
- Unknown (1) 
 
T1, three months# (n=25)  
1 drop-out; reason: 
- Terminal illness (1) 
5 did not respond; reasons: 
- Unknown (5) 
T2, six months# (n=25)  
2 drop-outs; reasons: 
- Time investment (1) 
- Unknown (1) 
3 did not respond; reasons: 
- Unknown (3) 
T3, 12 months# (n=25)  
3 did not respond; reasons: 
- Unknown (3) 
 
Intervention (n=28) 
6 intervention drop-outs; reasons: 
- Time investment too large (2) 
- Scheduling conflicts with training 
time (2) 







*: 39 women responded they had no interest in participating in the study without filling in the rest of the questionnaire 
#: The T0, T1, T2 and T3 questionnaires were sent zero, three, six and 12 months after randomization respectively 
*: 39 women responded they had no interest in participating in the study without fi lling in the rest of the 
questionnaire
#: The T0, T1, T2 and T3 questionnaires were sent zero, three, six and 12 months after randomization respectively
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Table 7.1: Baseline characteristics 
Variable Total (N = 65) MBSR (N = 34) CAU (N = 31)
Age, mean (SD) 47.7 (5.2) 47.0 (5.0) 48.5 (5.4)
BMI, mean (SD) 26.4 (4.9) 26.6 (4.0) 26.2 (5.8)
Married or cohabiting, n (%)
 No 7 (10.8) 1 (2.9) 6 (19.4)
 Yes 58 (89.2) 33 (97.1) 25 (80.6)
Children, n (%)
 No 10 (15.4) 2 (5.9) 8 (25.8)
 Yes 55 (84.6) 32 (94.1) 23 (74.2)
Children at home, n (%)
 No 16 (24.6) 4 (11.8) 12 (38.7)
 Yes 49 (75.4) 30 (88.2) 19 (61.3)
Higher education#, n (%)
 No 37 (56.9) 23 (67.6) 14 (45.2)
 Yes 28 (43.1) 11 (32.4) 17 (54.8)
Employment status, n (%)
 Unemployed 10 (15.4) 6 (17.6) 4 (12.9)
 Part-time 39 (60.0) 19 (55.9) 20 (64.5)
 Full-time 16 (24.6) 9 (26.5) 7 (22.6)
Smoker, n (%)
 No 56 (86.2) 31 (91.2) 25 (80.6)
 Yes 9 (13.8) 3 (8.8) 6 (19.4)
Alcohol consumption, n (%)
 0-1 unit / wk 36 (55.4) 17 (50.0) 19 (61.3)
 2-5 units /wk 24 (36.9) 16 (47.1) 8 (25.8)
 >6 units / wk 5 (7.7) 1 (2.9) 4 (12.9)
Exercise behavior, n (%)
 < 150 min / wk 12 (18.5) 8 (23.5) 4 (12.9)
 ≥ 150 min / wk 53 (81.5) 26 (76.5) 27 (87.1)
Underwent RRM, n (%)
 No 34 (52.3) 15 (44.1) 19 (61.3)
 Yes 31 (47.7) 19 (55.9) 12 (38.7)
Had BC, n (%)
 No 48 (73.8) 25 (73.5) 23 (74.2)
 Yes 17 (26.2) 9 (26.5) 8 (25.8)
Current HRT use, n (%)
 No 46 (70.8) 23 (67.6) 23 (74.2)
 Yes 19 (29.2) 11 (32.4) 8 (25.8)
PHQ-2, mean (SD) 1.3 (1.3) 1.4 (1.4) 1.1 (1.1)
GAD-7, mean (SD) 5.5 (4.5) 5.0 (3.5) 5.9 (5.3)
n = 65, One participant did not return the questionnaire at T0 or at subsequent time points, so baseline data were 
available for 65 participants. #: Higher education = (applied) university or higher. Abbreviations: SD, standard 
deviation; BMI, body mass index; RRM, risk-reducing mastectomy; BC, breast cancer; HRT, hormone replacement 
therapy; PHQ-2, Patient Health Questionnaire-2; GAD-7, Generalized Anxiety Disorder-7; MBSR, mindfulness-
based stress reduction; CAU, care as usual.
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Quality Control
Adherence by the trainers to the MBSR protocol, based on the audio recordings of 
several training sessions, was 80%. Participants receiving MBSR attended 79% of the 
MBSR sessions. The patient-reported adherence to daily homework was 75% during the 
intervention period, with participants reporting practicing for 33 minutes on average per 
day.
Primary and Secondary Outcomes
Table 7.2 summarizes the results of linear mixed modeling of the primary and secondary 
outcomes as a function of time, treatment, and interaction between time and treatment. 
Figure 7.2 visualizes the primary outcome estimates per time point and arm.
At randomization (T0), 63% (41/65) of participants reported five or more complaints with 
a bother score of six or higher (scale one to eight, data not shown). Statistically significant 
differences in improvements were found for the MENQOL total score (T1: 0.56, p = 0.04, 
T3: 0.56, p = 0.04) and the vasomotor (T1: 0.93, p = 0.04, T3: 0.98, p = 0.02) and physical 
(T1: 0.65, p = 0.01, T3: 0.69, p = 0.03) subscales in the MBSR group compared with the CAU 
group at three and 12 months after the start of the intervention (Table 7.2).
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Table 7.2: Linear mixed modeling of the primary and secondary outcomes as a function of 
time, treatment, and interaction







 CAU 3.8 (3.4–4.3) 3.8 (3.3–4.3) 3.7 (3.2–4.1) 3.9 (3.5–4.4)
 MBSR 4.1 (3.7–4.5) 3.5 (3.0–3.9) 3.7 (3.2–4.1) 3.6 (3.1–4.0)
 p 0.04* 0.31 0.04*
 Vasomotor subscale
 CAU 4.2 (3.6–4.8) 4.1 (3.5–4.8) 4.2 (3.5–4.8) 4.3 (3.7–4.9)
 MBSR 4.5 (4.0–5.1) 3.5 (2.9–4.1) 3.8 (3.1–4.4) 3.6 (3.0–4.2)
 p 0.04* 0.09 0.02*
 Psychosocial subscale
 CAU 3.7 (3.2–4.2) 3.6 (3.0–4.1) 3.6 (3.0–4.2) 3.8 (3.3–4.4)
 MBSR 3.8 (3.3–4.3) 3.4 (2.8–3.9) 3.6 (3.0–4.2) 3.7 (3.1–4.3)
 p 0.31 0.95 0.50
 Physical subscale
 CAU 3.5 (3.1–3.9) 3.6 (3.2–4.0) 3.5 (3.0–3.9) 3.8 (3.3–4.2)
 MBSR 3.5 (3.2–3.9) 3.0 (2.6–3.4) 3.3 (2.9–3.7) 3.2 (2.7–3.6)
 p 0.01* 0.32 0.03*
 Sexual subscale
 CAU 4.0 (3.1–4.8) 3.9 (3.0–4.7) 3.5 (2.7–4.3) 3.7 (2.9–4.4)
 MBSR 4.4 (3.6–5.2) 4.1 (3.3–4.9) 4.2 (3.4–5.0) 4.0 (3.2–4.8)





 CAU 14.7 (10.7–18.7) 15.6 (10.7–20.4) 12.2 (7.8–16.6) 12.4 (7.5–17.2)
 MBSR 16.9 (13.1–20.8) 16.7 (12.0–21.3) 17.2 (12.9–21.5) 17.6 (12.8–22.5)




 CAU 15.0 (11.9–18.1) 14.6 (11.3–17.8) 14.7 (11.3–18.2) 16.3 (13.0–19.6)
 MBSR 14.8 (11.9–17.8) 15.7 (12.6–18.8) 14.4 (11.0–17.8) 16.8 (13.5–20.0)
 p 0.40 0.92 0.75
 Desire subscale
 CAU 2.7 (2.3–3.1) 2.7 (2.3–3.1) 2.6 (2.2–3.1) 2.7 (2.2–3.1)
 MBSR 2.7 (2.3–3.1) 2.5 (2.1–3.0) 2.5 (2.0–2.9) 2.7 (2.2–3.1)
 p 0.63 0.66 0.97
 Arousal subscale
 CAU 2.8 (2.1–3.6) 2.8 (2.0–3.6) 2.8 (2.0–3.5) 3.2 (2.5–3.9)
 MBSR 3.0 (2.3–3.7) 3.2 (2.5–3.9) 2.8 (2.1–3.6) 3.2 (2.5–4.0)
 p 0.71 0.75 0.69
 Lubrication subscale
 CAU 2.9 (2.1–3.7) 2.7 (1.9–3.6) 3.0 (2.1–3.9) 3.0 (2.2–3.9)
 MBSR 2.8 (2.1–3.6) 3.1 (2.3–3.9) 2.9 (2.1–3.8) 3.8 (2.9–4.7)
 p 0.29 0.94 0.14
 Orgasm subscale
 CAU 3.0 (2.2–3.8) 2.8 (2.0–3.7) 2.8 (1.9–3.7) 3.4 (2.5–4.2)
 MBSR 2.9 (2.1–3.7) 3.3 (2.5–4.1) 3.1 (2.2–4.0) 3.7 (2.8–4.6)
 p 0.16 0.41 0.39
 Satisfaction subscale
 CAU 3.6 (3.0–4.1) 3.6 (3.0–4.2) 3.7 (3.1–4.4) 3.9 (3.3–4.6)
 MBSR 3.3 (2.7–3.8) 3.3 (2.7–3.9) 3.2 (2.6–3.9) 3.3 (2.7–3.9)
 p 1.00 0.71 0.38
 Pain subscale
 CAU 2.8 (1.8–3.7) 2.7 (1.7–3.7) 2.6 (1.6–3.6) 3.2 (2.3–4.1)
 MBSR 2.9 (2.0–3.8) 3.1 (2.2–4.0) 2.4 (1.5–3.4) 3.2 (2.2–4.1)
 p 0.51 0.53 0.75
Results are presented as means and 95% confidence intervals. n = 65, one participant did not return the 
questionnaire at T0 or at subsequent time points, resulting in baseline data being available for 65 participants. 
Reported p-values are reported for the group x time interactions in contrast to T0 in a linear mixed model. A 
p-value<0.05 (*) corresponds to a statistically significantly difference in the outcome measure between the 
MBSR and CAU groups from T0. Abbreviations: MENQOL, Menopause-Specific Quality of Life; FSDS, Female 
Sexual Distress Scale; FSFI, Female Sexual Functioning Index; CAU, care as usual; MBSR, mindfulness-based stress 
reduction.
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At six months, there was a non-significant trend for improvement in the MBSR group 
compared with the CAU group (p = 0.31), but there were no statistically significant 
differences in the psychosocial and sexual subscales of the MENQOL between the MBSR 
and CAU groups at any assessment point. A statistically non-significant but clinically 
relevant improvement (≥1 improvement in MENQOL total score) was also seen in 28.6% 
of the MBSR group compared with 16.7% of the CAU group at T1.
Regarding the secondary outcomes, 94% (61/65) of participants reported clinically 
relevant sexual dysfunction and 65% (42/65) reported clinically relevant sexual distress 
at randomization (T0; data not shown). However, no statistically significant differences 
were observed between the MBSR and CAU groups for the FSDS and FSFI total scores or 
subscales at any assessment point (Table 7.2).
After visual inspection of their respective Q-Q plots, the MENOL and FSDS could be 
considered to be normally distributed, but some non-normality could be observed in the 
distribution of FSFI scores at baseline (data not shown).
Discussion
Main Findings
In this randomized study, we showed that MBSR improved menopause-specific quality of 
life over both the short- and long-term in women with at least two moderate-to-severe 
menopausal symptoms after RRSO. However, MBSR did not improve sexual functioning or 
sexual distress.
Strengths and Limitations
The main strengths of this study are its randomized controlled design, the long-term 
follow-up over 12 months and that MBSR was conducted by certified trainers with 
high protocol adherence. Furthermore, this study is the first RCT to test a psychological 
intervention for alleviating menopausal complaints after RRSO, and is among the first to 
test the effect of that intervention on sexual symptoms associated with menopause.
The CAU group did not receive a blinded placebo intervention because it was impossible 
to blind participants to treatment allocation, which could induce a placebo effect. The 
use of a non-active control group receiving CAU and no other attention during the 
intervention period means that there was no control for the non-specific effects of MBSR 
(e.g., repeated contact with MBSR trainers and other group participants). Although no 
adverse effects were reported during the intervention, this was not routinely monitored or 
recorded, so cannot be excluded as a possibility. The FSFI questionnaire was observed to 
have some non-normality which could have resulted in an optimistic p-value estimation. 
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Since the FSFI was not found to be statistically significantly more improved in the MBSR 
arm compared to the CAU arm this would not impact the conclusions of the study. Finally, 
only one third of the eligible women chose to participate in this study, therefore a self-
selection bias is plausible which could have caused an overestimation of the intervention 
effect. 
Interpretation
This is the first study reporting the long-term effects of MBSR in women with menopausal 
symptoms after RRSO. Consistent with previous studies, we showed short-term 
improvement at three months (T1)32,33. However, our study is the first to report a persisting 
effect after one year, with improvement in menopause-specific quality of life at 12 months 
(T3) in the MBSR group compared with the CAU group. Although there was improvement 
from baseline in the MBSR group compared with the CAU group at the intermediate 
period of six months (T2), this was not statistically significant. Given that the change in 
effect at six months (T2) is small but in the same direction as the short- and long-term 
significant effect, it is likely that this is merely due to a statistical issue that could be solved 
with a larger sample size.  
On the interpretation of the MENQOL score, no specific studies have been published. 
However, the authors of the MENQOL questionnaire have suggested that a relevant 
clinical difference in MENQOL score could be 0.5 point change39. This suggestion 
was based on previous publications that compared patient-rated relevant change in 
symptoms with the corresponding change on a 7-point scale in other disease-specific 
QOL questionnaires (similar to the MENQOL questionnaire)44,45. A change of 0.5 or of 1.0 
was equivalent to patients reporting their symptoms to be ‘A little better’ and ‘Moderately 
better’, respectively44,45. 
In the current study the improvement in the total MENQOL score was mainly due to the 
improvement in the subscales of vasomotor symptoms (i.e. burden caused by hot flushes, 
night sweats and sweating in general) and physical symptoms (e.g. burden caused by 
stamina reduction, aches, urination frequency). The average difference on a 7-point scale 
in the vasomotor subscale and the physical subscale was 0.93 and 0.65 points, respectively. 
Therefore clinicians and patients could expect a modest to moderate reduction of 
perceived burden (i.e. bother) by vasomotor and physical symptoms of approximately 
13% and 9% respectively.
Clinicians and patients might want to be able to interpret the clinical impact of MBSR in 
terms of symptom frequency reduction. The MENQOL questionnaire only measures bother 
by menopausal symptoms, not frequency of menopausal symptoms. However some 
direction on the relationship between bother by and frequency of menopausal symptoms 
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can be given. In an earlier RCT that recorded both the change in hot flush frequency and 
change in MENQOL score, an improvement of approximately one point in the MENQOL 
score was found together with a 45% reduction of the hot flush frequency (an estimated 
reduction of approximately four hot flushes per day). However, the conclusion that one 
point change in MENQOL score represents the aforementioned reduction in hot flushes 
is too simplified. Changes in the other symptom domains or other (unknown) factors 
influence the total MENQOL score as well and therefore the relation between MENQOL 
score and hot flush frequency could be different in other circumstances.
The baseline level of sexual dysfunction was very high in this study, comparable to 
that reported after RRSO in other research, but much higher than that reported in the 
general population27,46. Unfortunately, our MBSR intervention did not improve this sexual 
dysfunction or distress. In contrast to this, previous controlled studies of mindfulness-based 
therapy for low sexual desire and arousal have found significant improvements in sexual 
functioning after the intervention47,48. Differences in study populations could explain the 
results, because the sexual problems in previous studies were of a psychological nature 
(e.g., lack of desire or low arousability), whereas the problems in the current population 
may have been of a mixed psychological and physiological nature (e.g., vaginal discomfort 
and loss of desire due to estrogen deprivation)47,48. However, consistent with our study, 
the earlier research also failed to show any improvement in sexual distress47,48. In a single-
armed pilot study, mindfulness-based therapy did improve sexual functioning after RRSO, 
but that study used an intervention specifically targeting sexual difficulties, rather than a 
general MBSR protocol as we used in this study49.
It has been proposed that mindfulness facilitates a more accepting, even-tempered 
state of being that helps decrease reactivity to stimuli50. Therefore, MBSR could work 
by reducing the degree to which vasomotor and physical symptoms are experienced 
as problematic or bothersome; in other words, by dampening the perceived severity of 
symptoms51. Indeed, it might be that MBSR also primarily affects the psychological aspects 
of sexual problems by improving cognitive appraisal rather than the by altering the actual 
physiological symptoms. This would explain why a previous study on the effect of MBSR 
on physiological arousal, as measured by vaginal photoplethysmography, did not find an 
improvement47. However, another hypothesis is that by decreasing stress, MBSR could 
diminish the frequency of hot flushes at a physiological level, because stress is thought 
to lower the threshold for heat dissipation responses51,52. Moreover, the effect of MBSR on 
the physiological stress response has been suggested by preliminary research indicating 
that it produces statistically significant reductions in cortisol levels and non-significant 
improvements in dehydroepiandrosterone-sulfate levels53,54.
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Conclusion
This study indicates that MBSR improves short- and long-term menopause-specific 
quality of life in women with menopausal complaints after surgical menopause induced 
by RRSO. We recommend that healthcare providers advocate MBSR in conjunction with 
HRT. However, MBSR may be especially relevant for breast cancer survivors or in other 
settings when HRT is contraindicated.
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Introduction
This thesis aims to increase understanding of the factors that influence the uptake and 
timing of risk-reducing surgery in BRCA1/2 mutation carriers (Part I) and to investigate 
the effectiveness of psychological interventions in alleviating menopausal complaints 
after risk-reducing salpingo-oophorectomy (RRSO) (Part II). Firstly, this chapter will give 
a brief summary of the findings presented in the previous research chapters. Then, the 
findings of the two parts of the thesis are placed into the context of current literature, the 
methodology is reconsidered and the implications for practice and future research are 
discussed.
Summary
Part I: Factors associated with the uptake of risk-reducing surgery
As described in the general introduction (chapter 1), more knowledge on the factors 
that influence the complex decision on whether or not to undergo risk-reducing surgery is 
needed. These factors are relevant during counseling and in providing optimal decisional 
support. Next to identifying sociodemographic factors, this thesis aimed to study the 
influence of additional psychological factors and stopping with offering ovarian cancer 
screening on the uptake and timing of risk-reducing surgery.
In chapter 2, it was analyzed which patient characteristics are associated with an earlier 
decision for risk-reducing mastectomy (RRM) in a consecutive series of 407 BRCA1/2 
mutation carriers who visited our family cancer clinic between 1994 and 2011. It was found 
that a cumulative percentage of 36% of all women chose to undergo RRM within the first 
five years after disclosure of their DNA test results. Earlier uptake of RRM was associated 
with women being younger than 50 years of age, having had previous unilateral breast 
cancer, having a mother with breast cancer and having undergone unilateral therapeutic 
mastectomy instead of lumpectomy (in case of previous unilateral breast cancer). These 
results suggest that women with a personal or familial history with cancer seem to choose 
RRM earlier in comparison to women who do not have this experience. We hypothesized 
that these first-hand experiences with the impact of breast cancer, resulting in an increase 
of cancer specific worry1, speed up the uptake of RMM.
Chapter 3 is focused on exploring the possible association of psychological factors, such as 
affect, with the intention to choose RRM. A cohort of 486 cancer-unaffected women with a 
family history of breast cancer filled out questionnaires concerning their breast cancer risk, 
prior to their intake consultation with a clinical geneticist. The battery of questionnaires 
consisted of the cancer worry scale, positive and negative affect scale, perceived personal 
control scale, hospital anxiety and depression scale and state anxiety scale and questions 
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regarding socio-demographic characteristics, family history, risk perception and RRM 
intention. We found that psychological factors associated with intention to undergo RRM 
were high positive affect, high negative affect, high cancer worry, high perceived personal 
control and high risk-perception. It is likely that affect plays a role in decision-making, 
as it provides means to make quick and efficient decisions in complex situations2,3. The 
hypothesis behind this is that women process risk information in two ways, namely by 
deliberating the risk in a cognitive and literal manner and by understanding the risk in 
an intuitive manner. The intuitive understanding of risk is often derived from experiences 
with similar events in the past (e.g. a family member with breast cancer) that have become 
“tagged” with affective meaning. This affective tag can be used as an intuitive shortcut to 
reach a decision2. 
In chapter 4, the effect of stopping ovarian cancer screening on the timing and uptake 
of RRSO was explored. A higher percentage of women underwent RRSO and did so more 
often within the recommended age range. Other factors that led to an earlier uptake of 
RRSO were having two or more children and having reached the recommended age range 
for RRSO. The findings of this study closely reflect the effect of a change in counselling 
by health care providers. Women who are counseled unambiguously that RRSO is the 
only effective risk-reducing strategy and is best performed within a certain age range 
after completing childbearing will follow this advice more often. Furthermore, from the 
patient’s perspective, being a mother also means having the responsibility to care for 
children. This factor might also make women more inclined to choose RRSO within the 
recommended age range. 
Part II: Psychological interventions alleviating menopausal symptoms after RRSO
In the second part of this thesis the consequences of surgical menopause after RRSO at 
premenopausal age are discussed. Firstly, we reported that the severity and the duration 
of symptoms is an often overlooked topic. Subsequently, this thesis aimed to investigate 
the effectiveness of psychological therapies on menopausal and sexual complaints in 
women after surgical menopause following RRSO. This is especially relevant as hormone 
replacement therapy (HRT) was found not to eliminate menopausal symptoms to a pre-
menopausal level in women after RRSO and is contraindicated in breast cancer survivors4,5.
Chapter 5 describes a cross-sectional study on the severity and duration of menopausal 
symptoms in previously premenopausal women. At a mean follow-up time of 7.9 
years after RRSO, 69% (137/199) of the included women reported moderate to severe 
symptoms on the menopause rating scale. Of these symptoms, urogenital symptoms 
(e.g. dysuria, vaginal dryness, itching, burning and dyspareunia) were most frequently 
mentioned, followed by psychological symptoms (e.g. depressive mood, irritability, 
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anxiety). Furthermore, being a breast cancer survivor was associated with moderate to 
severe menopausal symptoms after RRSO. 
In chapter 6, a systematic literature review and meta-analysis is described on the existing 
evidence on the effectiveness of psychological interventions in reducing symptoms 
associated with menopause in natural or treatment-induced menopausal women. 
Psychological interventions were found to be effective as an alternative or an addition to 
HRT in reducing natural and breast cancer treatment-induced menopausal complaints. The 
work described in this chapter is a step towards clinical implementation of psychological 
treatment of menopausal symptoms. However, lacking were studies investigating the 
long-term effects of psychological interventions on menopausal symptoms and the 
effectiveness of psychological interventions in other populations such as women with 
menopausal complaints after RRSO. 
This led to the conception of the last study of this thesis, which is described in chapter 7. 
This study is a randomized controlled trial investigating the short and long-term effects 
of mindfulness-based stress reduction (MBSR) on menopausal quality of life, sexual 
functioning and sexual distress after RRSO. Our results showed that MBSR did indeed 
improve short- and long-term menopause specific quality of life when compared to 
care as usual, even after one year. However, MBSR did not improve sexual functioning 
or sexual distress. From this we concluded that in the case of non-sexual menopausal 
complaints, MBSR can be advised by healthcare providers as an alternative or addition to 
HRT, especially in breast cancer survivors. 
Context of other literature 
Part I: Factors associated with the uptake of risk-reducing surgery
In part I of this thesis we aimed to identify the factors that influence (the timing of ) 
decisions about risk-reducing surgeries in women with an elevated risk for breast and 
ovarian cancer. To understand the findings of part I of this thesis it is necessary to place 
them into the context of literature on decision-making in the field of risk-reducing surgery. 
In the following paragraph we will approach this matter from two perspectives, namely: 
the patient’s and the physician’s perspective and their role in shared decision-making. 
Shared decision-making on risk-reducing surgery
Shared decision-making in risk-reducing surgery aims to foster the patient’s self-
determination and autonomy. In literature, the approach is describes as a clinician 
sharing the available medical information on risk-reducing options and their differences 
with the patient and a patient sharing information on her personal circumstances, values 
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and preferences6. The goal is reached by ensuring the patient is well-informed and receives 
support in deliberating on the advantages and disadvantages of several options in the 
context of their own life6,7. From this description of shared decision-making it becomes 
clear that in order to reach a shared decision, two perspectives need to be taken into 
account, namely the physician’s and the patient’s perspective. These two perspectives 
combined lead to the preferred risk management option with regard to reducing the risk 
of developing or dying from cancer.
Uptake of risk-reducing surgery; patients’ perspectives 
The physician’s perspective in decision-making consists of biomedical information, such as 
expected benefits and harms of risk-reducing options in terms of survival, and the patient’s 
perspective consists of personal circumstances, values and preferences. This perspective 
is often shaped by previous experiences to which an affective meaning is assigned 
(chapter 2 & 3). Specifically, when deciding on risk-reducing surgery in case of hereditary 
breast and ovarian cancer risk, previous experiences with cancer gain importance in the 
decision-making process. In line with our results that women with a personal or family 
history of cancer choose RRM more often (chapter 2), a qualitative study conducted in 
20 women at high risk for hereditary breast cancer, found that family experiences were 
important in how information about RRM was processed8. Also, women’s perception of 
their own cancer risk, perception of the consequences of developing breast cancer and 
their risk-reducing strategy decisions were influenced by their experiences with cancer in 
their family8. 
As described in the summary of chapter 3, our hypothesis was that patients process 
the information on risk in a cognitive, literal manner, as well as in an intuitive, affective 
manner. The context of women’s family cancer history relates more to the intuitive 
manner of interpreting risk. This is substantiated by a qualitative study interviewing 36 
unaffected women from high-risk breast cancer families. From this study it is clear, that 
although women’s cognitive understanding of their risk is accurate, this understanding of 
risk information is of secondary importance in their decision-making process2. Instead, it 
was found that risk perception and subsequent decision-making about risk-management 
options, are primarily driven by an intuitive understanding of their risk. This intuitive 
understanding of risk is closely linked with affective meaning elicited by past experiences, 
such as breast cancer in family members2. 
The fact that the affective understanding of risks plays an important role in decision-
making from the patient’s perspective, makes miscommunication between the 
patient and her physician more likely. Especially when the physician is not aware of 
the importance of the affective understanding of risks. The physician aims to provide 
facts and figures to explain the medical situation to the patient, however in light of 
Summary and general discussion
8
|   141 
contextual factors a patient might intuitively interpret this risk to be much higher or 
lower than what the physician intended to bring across. From the physician’s perspective, 
this could lead to under- or overutilization of risk-management options when left 
unaddressed. Moreover, a certain risk could be undesirable from a biomedical standpoint, 
but acceptable from the patient’s perspective in the context of her life and vice versa. 
Lastly, medical decision-making is often complicated by the fact that more than one type 
of risk is relevant for the patient and/or the physician. Such as the risks of surgery, the risk 
of developing a disease and/or the risk of dying from a disease. Time-dependent factors 
further complicate this decision as cancer risks change throughout the patient’s life as 
well as the impact developing cancer or risk-reducing strategies have in different life 
stages (e.g. before completing childbearing, while having young children).
Uptake of risk-reducing surgery; physician’s perspective
After discussing the patient’s perspective, this paragraph will describe the influence of the 
physician’s perspective on risk-management decision-making. By stopping ovarian cancer 
screening in BRCA1/2 mutation carriers in 2009, the physicians of our family cancer clinic 
(FCC) aimed to prevent ovarian cancer by subsequent underutilization of RRSO as a result 
of a false sense of security. The strategy in our FCC was twofold, namely by communicating 
biomedical information (e.g. ovarian cancer screening does not detect cancer in an early 
and curable stage, timely RRSO is currently the only effective option for preventing death 
due to ovarian cancer), but also by jointly discussing the affective interpretation assigned 
to this situation and what this means to the patient in the context of their life. Using this 
strategy, a best course of action was determined jointly by the patient and the physician. 
We observed that after stopping ovarian cancer screening, the uptake of RRSO within 
the recommended age range increased (chapter 4). We hypothesized that this two-fold 
strategy increased patients’ knowledge on the ineffectiveness of ovarian cancer screening 
and supported patients to make value-consistent decisions. This is in line with findings 
from the study of Pai et al., who found that choosing RRSO over ovarian cancer screening 
was related to an increased awareness of the ineffectiveness of ovarian cancer screening9. 
Traditionally, the focus of physicians and researchers has been on communicating the 
physician’s perspective (e.g. biomedical facts and figures) and checking whether this 
perspective was communicated correctly in terms of for example the correct recall 
of risk information10–12. Part I of this thesis makes a case for incorporating the patient’s 
perspective in the shared decision-making process. By doing so, this may improve patient-
physician communication, increase patients’ understanding and empower patients to 
make decisions that are optimal given the individual circumstances of the patient. 
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Part II: Psychological interventions alleviating menopausal symptoms after RRSO
In part II of this thesis severity and duration of menopausal symptoms after RRSO and 
possible interventions to alleviate these symptoms are investigated. A common thread in 
part II is sexual health after (surgical) menopause. The findings of part II of this thesis will be 
discussed and placed in the context of adjacent literature concerning sexual health after 
(surgical) menopause. The rationale behind high-lighting specifically this theme is that 
sexual health or lack thereof has a large impact on women’s lives, but nonetheless is often 
overlooked. 
Sexual health after (surgical) menopause 
After RRSO, urogenital symptoms such as vaginal dryness and dyspareunia do not seem to 
diminish with time (chapter 5) and sexual dysfunction and sexual distress after RRSO were 
reported by a large majority of women in the RCT presented in this thesis (chapter 7). This 
high proportion of women reporting sexual dysfunction and sexual distress could in part 
be due to selection bias, however a cross-sectional study also found a high prevalence 
of sexual dysfunction in women after RRSO4. In women with a personal history of breast 
cancer, sexual symptoms after RRSO seem to be even more pronounced (chapter 5), 
although mixed results in literature have been reported4,13–15.
A study in women who underwent RRSO reports that most women were merely counseled 
on menopausal symptoms, such as experiencing hot flushes after RRSO16. However, a large 
majority of women were at no point (i.e. pre or post-surgery) counseled on the impact of 
RRSO on their sex life by their physician16. Retrospectively, a majority of women would 
have liked a more thorough discussion on the impact of RRSO on their sexual health 
and more information on interventions to maintain or improve their sexual health16. 
Furthermore, sexual outcomes in intervention studies aimed at alleviating menopausal 
symptoms seem to be lacking (chapter 6). Although physicians subscribe to the view that 
the impact on sexuality should be routinely discussed, many reported lack of time and 
uncertainty on which member of the multidisciplinary team should take responsibility 
for this discussion17,18. The lack of discussing expectations about the impact on sexual 
functioning creates the impression that barriers to discuss sexual health might be present. 
Barriers to discussing sexual health after (surgical) menopause
A narrative review on sexual health communication during cancer care identified three 
types of barriers from the physician’s perspective, namely: patient characteristics, 
physician characteristics and system issues17. Based on certain patient characteristics, such 
as: gender, age, sexual orientation and relationship status, physicians may make incorrect 
assumptions about the patient’s wishes regarding discussing sexual health17,19. Physician 
characteristics that have repeatedly been associated with lack of routine discussion of 
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sexual health are a lack of knowledge, skills and experience concerning discussing sexual 
health issues17,20. To bridge this gap, initial steps in offering unexperienced physicians 
practical guidelines already have been made17,21. Lastly, system issues such as time 
constraints and issues with the availability of effective interventions were indicated as 
barriers to discuss sexual health with women during cancer care. 
One of the difficulties of finding effective interventions for women with sexual health 
issues is that these issues are often a mix of physiological issues such as vaginal dryness 
and psychological complaints such as a lack of sexual arousal and sexual satisfaction4,13. 
Therefore, it is not surprising that the simple use of a pharmacological option such as 
HRT was not found to be a predictor of the severity of symptoms after RRSO (chapter 5). 
This corresponds with several studies that found that HRT does not entirely ameliorate 
menopausal symptoms after RRSO to a premenopausal level4,22,23. A study by Tucker et al., 
that specifically investigated sexual function after RRSO, found that HRT use after RRSO 
was associated with lower rates of dyspareunia and less severe complaints of vaginal 
dryness, when compared to no HRT use after RRSO. However HRT use had no effect on 
orgasm, desire, arousal or satisfaction levels24. 
By incorporating psychological interventions, this thesis aimed to identify an effective 
intervention to resolve sexual health problems after RRSO (chapter 6 & 7). An effective 
intervention was not yet found, however the field of psychological interventions to 
resolve sexual health issues is promising25,26. For this reason, the search for an effective 
intervention continues, as will be discussed in the paragraph “future research directions” 
below. However, the success of an intervention does not only depend on the availability 
of effective options, but equally on whether the intervention is delivered to the right 
women at the right time. Sexual health issues need to be routinely discussed before and 
after surgery in order to manage women’s expectations more sufficiently.
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Methodological considerations 
Part I: Factors associated with the uptake of risk-reducing surgery
In part I of this thesis we used prospectively gathered databases to identify predictors of 
choosing risk-reducing surgery. It is important to consider the underlying methodology 
of the research conducted in this part to be better able to interpret its conclusions. 
The University Medical Center of Groningen (UMCG) is the only university hospital in the 
Northern Netherlands and has a very large referral area. The FCC of the UMCG is a center of 
expertise on hereditary cancer and has gathered data on all hereditary breast and ovarian 
cancer cases prospectively since 1994, using a localized electronic patient record system. 
This system ensured the prospective data gathering for research purposes with high data 
quality when compared to retrospective data collection. Only for a small portion of the 
cases the data had to be completed retrospectively and this is also apparent from the low 
amount of missing data. The data gathered in the FCC lays the foundation of the research 
described in chapter 2 and 4.
When analyzing the uptake of risk-reducing surgeries, the follow-up time is often different 
between patients and between different studies. Women with a longer follow-up time 
have more opportunity to choose risk-reducing surgery. Therefore, having a long or short 
follow-up can lead to an over- or underestimation of the percentage of women choosing 
risk-reducing surgery. However, most women who underwent risk-reducing surgery 
did so after having reached the recommended age, which reduces the dependency on 
duration of follow-up. In other words, the time in follow-up after having reached the 
recommended age is an important predictor for uptake. A time-to-event analysis (i.e. 
Cox regression), which was performed in this thesis, takes follow-up time into account 
by correcting for differences in duration of follow-up between women. For this type of 
analysis it is necessary that not only the uptake of risk-reducing surgery is recorded, but 
also its timing since entering the FCC. Another advantage of our FCC database is that this 
could be determined reliably. 
Furthermore, the FCC database, which has been prospectively including women for over 
20 years, is based on a large catchment area and has a long follow-up. This has resulted 
in large sample sizes, which allowed for the identification of independent predictors of 
the uptake of risk reducing surgery using multivariate statistical analyses. The long period 
of patient recruitment could potentially lead to a more heterogeneous sample which 
is not entirely representative of patients today. For example, over the years there have 
been changes in the guidelines for recommending risk-management options and the 
guidelines regarding DNA testing. However, the inclusion criteria were kept constant 
to reduce this source of heterogeneity. Furthermore, due to the high quality of data 
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registration and adherence to the counselling guidelines, the effect of a change in RRSO 
counselling guidelines could be studied in detail in chapter 4 of this thesis.
It is important to note that the predictors considered in chapter 2 and 4 were only 
recorded at baseline. Therefore some of these characteristics may have changed during 
follow-up, which could have influenced the results. For example, it was found that having 
a mother with breast cancer was a predictor for undergoing RRM. Women whose mother 
developed breast cancer during follow-up would have been recorded as having a mother 
unaffected by breast cancer. However, the fact that a family member has developed 
cancer could have influenced the decision-making process. This could have led to a slight 
underestimation of the predictors at the time the decision was made. Furthermore, all 
family cancer history data relied to some degree on the accurate reporting of patients 
themselves.
Lastly, the majority of the studies in this thesis had actually ‘choosing and undergoing 
risk-reducing surgery’ as their outcome measure, however one study had the ‘intention 
to undergo risk-reducing surgery’ as reported by women as an outcome (chapter 3). This 
intention was recorded prior to receiving their DNA test results. While the intention to 
undergo RRM and undergoing RRM in the case of a proven BRCA1/2 mutation is likely 
to be strongly correlated, they cannot be assumed to be identical. Therefore, the found 
predictors of the intention to undergo RRM could be slightly different from the predictors 
to actually undergo RRM.
Part II: Psychological interventions alleviating menopausal symptoms after RRSO
Part II of this thesis largely focused on psychological interventions to improve menopause-
related quality of life. This was done firstly by analyzing RCTs in the context of a systematic 
literature review and meta-analysis and secondly through conducting an RCT specifically 
for the target population of this thesis. In general, certain methodological issues are known 
to affect the quality of RCTs, such as: random assignment of subjects to treatment groups, 
concealment of allocation, blinding of researchers and subjects to allocation etcetera.
However when investigating psychological interventions such as a mindfulness-based 
intervention, certain specific methodological difficulties are encountered27. Many studies 
do not report the participant’s attendance, participant’s homework adherence or the 
trainer’s adherence to the protocol of the intervention. In these studies it is unclear 
whether the intervention was delivered in the intended intensity (i.e. “dosage”). Therefore 
an underestimation of the effect of the intervention could have occurred. Furthermore, 
many studies do not have an active control group to ascertain the influence of non-
specific effects (e.g. peer support)27–29. 
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In the RCT described in chapter 7, specific measures were taken to avoid the above 
mentioned methodological difficulties. To ascertain whether the intervention was offered 
as intended, the intervention was delivered according to a detailed protocol, adherence 
to the protocol by the trainers was assessed using audio recordings, and participants’ 
attendance and homework compliance was recorded. A strength of this study was the 
long duration of follow-up in order to assess the long term effect of the intervention, 
beyond the intervention itself. Long-term follow-up was not present in most other 
RCT’s concerning effectiveness of psychological intervention on menopausal symptoms 
(chapter 6). 
The RCT was designed as a pragmatic trial. The control condition was not an active 
comparator condition but consisted of care-as-usual. Although factors such as the effect 
of being in a group setting and having contact with peers and trainers were not controlled 
for in this design, it does give an estimation of the effectiveness of the intervention in daily 
clinical practice. This also holds true for potential self-selection bias as this could in part be 
present in clinical practice as well.
Clinical implications
Part I: Factors associated with the uptake of risk-reducing surgery
Based on the research in part I of this thesis we have a better understanding of which factors 
influence the uptake and timing of risk-reducing surgery. In the clinic, this understanding 
can be incorporated into the counseling of women who are at high risk for developing 
breast and ovarian cancer. Besides, the findings of this thesis could be used to encourage 
physicians who still offer ovarian cancer screening to discontinue this ineffective practice 
and instead offer timely RRSO.
As described earlier, shared decision-making is an approach in which a clinician 
shares  medical information (i.e. physician’s perspective) and a patient shares her 
personal circumstances, context, family history, values and preferences (i.e. the patient’s 
perspective). The patient and the clinician jointly consider, deliberate and decide on (the 
timing of ) the most appropriate risk-management strategy for this particular patient30. 
The focus traditionally has been on conveying the most precise risk percentages to 
patients and evaluating the quality of counseling based on the accuracy of patients’ 
literal recall. However, this insufficiently incorporates the patient’s personal context and 
perspective. This thesis emphasizes that psychological factors such as affect, cancer worry 
and perceived personal control may be the most influential factors in the decision-making 
process from the patient’s perspective. To empower women to reach a fully informed 
decision that is both medically adequate as well as consistent with values from their own 
perspective, these factors should be addressed and weighted during counselling.
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Patients might very well have a sufficient cognitive understanding of the information 
on risks, but when exploring the affective meaning patients attach to this information, 
an incongruence in risk-interpretation could still be present that needs to be resolved. 
As mentioned before, it is vital that healthcare provider’s counseling incorporates both 
the doctor’s and patient’s perspectives. The doctor’s perspective can be incorporated 
through the discussion of accurate and objective biomedical information on age-related 
cancer risks and effective preventive strategies (chapter 4). The patient’s perspective can 
be incorporated through a thorough discussion of influential factors such as affective 
meaning high-risk women assign to their situation or the impact of first-hand experience 
with cancer (chapter 2 & 3). The alignment of these perspectives is an implementation of 
shared decision-making and optimal decisional support. 
Part II: Psychological interventions alleviating menopausal symptoms after RRSO 
In this thesis psychological interventions were shown to have a moderate effect on hot 
flush bother, menopausal symptoms and menopause-specific quality of life (chapter 
6 & 7). As such, psychological therapies could be one of the options offered to women 
suffering from menopausal complaints, either in conjunction with HRT or as an alternative 
to HRT when contraindicated such as in breast cancer survivors. Furthermore, breast 
cancer survivors often experience more severe complaints for a longer duration of time 
after RRSO (chapter 5) and therefore could especially be in need for an alternative to HRT. 
In deciding for which women this psychological intervention could be most beneficial, 
a few matters can be taken into consideration. Firstly, only bother by hot flushes, not 
frequency, decreased after psychological intervention as shown in chapter 6. When 
offering this type of intervention this should be communicated to the patient to manage 
realistic expectations. When selecting women for these types of interventions, the level of 
bother by hot flushes and not the frequency should be leading. This might also be a logical 
criterion in light of the fact that bother by hot flushes might be the most appropriate 
measure of quality of life in women suffering from vasomotor symptoms31,32. Secondly, 
there is a lack of data on the effect of psychological therapies on sexual outcomes, so no 
conclusions could be drawn concerning this outcome in chapter 6. Unfortunately, the 
general MBSR program did not improve sexual functioning or sexual distress in chapter 
7. Therefore, it is concluded that current psychological therapies are best recommended 
to women with non-sexual menopausal complaints after RRSO. 
Future research directions 
Part I: Factors associated with the uptake of risk-reducing surgery
It is important that healthcare providers are aware of both the physician’s and the patient’s 
perspectives. A more formal way to incorporate the physician’s perspective (i.e. medical/
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factual considerations) and the patient’s perspective (i.e. personal circumstances, values 
and preferences) is by using a decision support tool in conjunction with conventional 
counselling. Decision support tools for high-risk women that are currently available 
mostly focus on providing information about cancer risks, risk-reduction options and 
attaching values to the pros and cons of (timing of ) certain risk-reducing options. Current 
tools do not or only slightly focus on congruence between patients’ values stemming 
from the broader context of their life, such as past experiences and future aspirations or 
personality characteristics33. If these decision support tools are upgraded to include the 
patient’s perspective, they could be beneficial in aligning the cognitive and affective parts 
of the decision-making process. 
To develop these types of tools in full, more insight into the decision-making process 
is needed. Especially the role of psychological factors such as emotions, personality 
characteristics and social factors, such as caregiver role and social support, is needed to 
further personalize counseling to improve the decision-making process. Quantitative 
research could lay a basis for identifying the type of patients’ factors that are associated 
with the decision-making process, building on current research such as presented in this 
thesis. In-depth qualitative research is needed to give insight into the different aspects of 
the women’s perspective on how these factors influence their decisions. 
Furthermore, prospective longitudinal research on the relation between choosing 
certain risk-reducing options on physical, psychological and social outcomes should be 
incorporated into these decision tools. This improvement could lead to more specific 
counseling on the broader consequences of a certain decision, which are not only 
confined to medical pros and cons. A last consideration for future research is that, to the 
best of our knowledge, the role of the partner in the decision-making process regarding 
risk-reducing surgery has not been investigated. As studies on decision-making about 
breast reconstruction after cancer show that the partner has a consultative role, research 
on optimal shared decision-making concerning risk-reducing surgery should investigate 
the involvement of the partner in this process34. 
Part II: Psychological interventions alleviating menopausal symptoms after RRSO
What remains unclear and could be the focus of future research is the effectiveness of 
mindfulness, cognitive-behavioral and behavior-based interventions in alleviating 
menopausal complaints after RRSO. This type of research could answer questions such as 
which type of intervention is most effective and what moderates this effect (e.g. what type 
of patient benefits most from a certain type of intervention). Furthermore, new research 
should aim to investigate long-term outcomes, include populations with other causes of 
menopausal symptoms and include active control groups to control for the non-specific 
effects (e.g. contact with peers). 
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Sexual functioning is an important aspect of quality of life. At this moment we have no 
definite answer on how to treat sexual symptoms after RRSO. This is in part because 
randomized controlled trials investigating the effect of psychological therapies in 
menopausal women rarely report sexual outcomes. Also, HRT does not ameliorate sexual 
symptoms entirely and is contraindicated in breast cancer survivors, who are prevalent 
among BRCA1/2 mutation carriers. What is more, the mindfulness based stress reduction 
intervention tested in this thesis was not effective in alleviating sexual dysfunction and 
sexual distress after RRSO. Seeing that a large proportion of women experience severe 
and persistent sexual complaints after RRSO makes it imperative that the search for an 
effective intervention must continue. A few general suggestions for future research can 
be made. Firstly, involving the partner of women suffering from menopausal complaints 
could lead to a more effective intervention, as relationship satisfaction is an important 
predictor of sexual functioning4. Secondly, it could be beneficial to combine treatment 
modalities such as psychological and pharmacological treatments, as sexuality has 
psychological as well as physical aspects35. Lastly, HRT does not improve the domains of 
sexuality concerning sexual pleasure (e.g. desire and satisfaction)4,22–24,36,37. Therefore, it is 
recommended that future research should not merely focus on improving the physical 
response (e.g. vaginal lubrication), but on designing psychological interventions that are 
effective in improving all domains of female sexual functioning38. 
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Vrouwen met een BRCA1/2 genmutatie hebben een verhoogd risico op het ontwikkelen van 
borst- en eierstokkanker. Vrouwen met deze erfelijke aanleg voor borst- en eierstokkanker 
wordt aangeraden om hun borsten regelmatig te laten controleren op borstkanker of om 
hun borsten preventief te laten verwijderen. Met betrekking tot de eierstokken wordt 
geadviseerd deze preventief weg te laten halen, omdat controle van de eierstokken niet 
effectief is gebleken in het vroegtijdig opsporen van eierstokkanker. Het wel of niet 
preventief laten verwijderen van de borsten en/of eierstokken is een erg ingrijpende 
keuze. Bij de keuze om de borsten preventief te laten verwijderen speelt enerzijds 
mee dat na een preventieve borstverwijdering de kans op borstkanker erg klein is, 
maar anderzijds het kan een negatieve invloed hebben op de lichaamsbeleving en 
seksualiteit. Vrouwen die kiezen om hun eierstokken te laten verwijderen hebben 
eveneens een erg kleine kans om alsnog eierstokkanker te ontwikkelen. Echter komen 
deze vrouwen als gevolg van de eierstokverwijdering direct in de overgang terecht. 
Dit proefschrift richt zich op welke factoren van invloed zijn op het al dan niet preventief 
laten verwijderen van borsten en/of eierstokken en op welke gevolgen het verwijderen 
van de eierstokken heeft. Hieronder volgt een korte samenvatting van de verschillende 
hoofdstukken in deze thesis. 
DEEL I:  
FACTOREN DIE DE KEUZE BEÏNVLOEDEN OM BORSTEN EN/OF 
EIERSTOKKEN PREVENTIEF TE VERWIJDEREN
Om vrouwen te ondersteunen bij hun keuze om wel of niet hun borsten en/of eierstokken 
te laten verwijderen is het belangrijk om te weten welke factoren hun keuze beïnvloeden. 
Tijdens de gesprekken met de behandelend arts kan dan extra aandacht aan deze 
factoren worden besteed. In hoofdstuk 2 is onderzocht wat de karakteristieken waren van 
vrouwen die sneller kozen voor een preventieve borstverwijdering na het bekend worden 
van hun BRCA1/2 genmutatie. Dit is onderzocht in een groep van 407 vrouwen en uit dit 
onderzoek bleek allereerst dat ongeveer 36% van alle vrouwen hun borsten binnen vijf 
jaar preventief liet verwijderen nadat ze hoorden dat ze een BRCA1/2 genmutatie hadden. 
Verder kozen vrouwen sneller voor een preventieve borstverwijdering als ze jonger dan 
50 jaar waren, een moeder hadden met borstkanker, al eens borstkanker aan de andere 
borst hadden gehad en wanneer ze als behandeling van een eerdere borstkanker al een 
van hun borsten hadden laten verwijderen. Hieruit kunnen we afleiden dat vrouwen met 
een persoonlijke ervaring met kanker of een ervaring met kanker in hun familie eerder 
kiezen voor een preventieve borstverwijdering dan vrouwen die dit niet hebben. We 
verwachten dat dit komt door dat vrouwen met een dergelijke ervaring zich meer zorgen 
maken over het krijgen van kanker en daarom sneller hun borsten laten verwijderen.
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Hoofdstuk 3 richt zich op de psychologische factoren die de keuze voor wel of niet 
preventieve borstverwijdering beïnvloeden. Deze factoren zijn onderzocht in een groep 
van 486 vrouwen die zelf nog nooit kanker hadden gehad, maar wel familieleden hebben 
die borstkanker hebben gehad. Voor ze getest werden op een genetische aanleg voor 
borst- en eierstokkanker vulden deze vrouwen een vragenlijst in met daarin de vraag of 
ze preventieve borstverwijdering zouden kiezen als blijkt dat ze inderdaad een BRCA1/2 
genmutatie hebben. Ook vulden ze vragen in over psychologische factoren zoals hoeveel 
zorgen ze zich maken over het krijgen van kanker, hun gemoedstoestand, het ervaren 
van controle over hun persoonlijke situatie, angstigheid en depressie. Hieruit bleek dat 
vrouwen met een zeer negatieve of juist een zeer positieve gemoedstoestand vaker de 
intentie uitspraken om hun borsten te laten verwijderen indien er sprake zou zijn van 
een BRCA1/2 genmutatie. Daarnaast hadden vrouwen vaker de intentie om hun borsten 
te laten verwijderen als zij zich veel zorgen maken over het krijgen van kanker, zij de 
kans hoog inschatten om kanker te krijgen en wanneer zij een hoge mate van controle 
ervaarden over hun persoonlijke situatie. 
De gemoedstoestand die iemand ervaart wanneer zij worden geconfronteerd met een 
bepaalde complexe situatie kan helpen om in een dergelijke situatie toch een snelle en 
effectieve beslissing te kunnen nemen. Dit komt omdat vrouwen informatie over hun risico 
op kanker op twee manieren verwerken, namelijk door het risico op een verstandelijk 
niveau te begrijpen en door het risico tegelijkertijd op een intuïtieve manier te begrijpen. 
Dit intuïtieve begrip wordt waarschijnlijk gekleurd door ervaringen met vergelijkbare 
gebeurtenissen in het verleden (bijvoorbeeld een familielid met borstkanker). Deze 
gebeurtenissen dragen een bepaalde emotionele lading met zich mee, welke de 
gemoedstoestand beïnvloed en daarmee waarschijnlijk ook de beslissing om tot actie 
over te gaan. 
Zoals eerder genoemd werd, is het met eierstokcontroles niet goed mogelijk om 
eierstokkanker in een vroeg stadium, wanneer de genezingskans nog hoog is, te 
ontdekken. Daarmee is eierstokcontrole weinig zinvol en wordt dit om die reden niet meer 
uitgevoerd in Universitair Medisch Centrum Groningen. In hoofdstuk 4 werd onderzocht 
wat het effect is van het stoppen van eierstokcontroles op de keuzen om de eierstokken 
preventief te laten verwijderen. Er werd geconstateerd dat sinds eierstokcontroles niet 
meer worden uitgevoerd vrouwen vaker kiezen om hun eierstokken te verwijderen en dit 
vaker deden op een leeftijd voordat het risico op eierstokkanker sterk toeneemt. Vrouwen 
met twee of meer kinderen kozen het snelst voor risico reducerende eierstokverwijdering 
nadat het bekend werd dat zij een BRCA1/2 mutatie hadden. Dit onderzoek toont aan 
dat vrouwen sneller overgaan tot preventieve eierstokverwijdering wanneer zij worden 
voorgelicht dat eierstokcontroles niet effectief zijn. Het feit dat vrouwen voor de leeftijd 
waarop het risico op eierstokkanker toeneemt deze keuze maken is gunstig. Blijkbaar is 
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er geen sprake van het “uit het oog raken” van vrouwen wanneer zij minder vaak contact 
hebben met hun behandelend arts vanwege het wegvallen van de periodieke controles. 
DEEL II:  
PSYCHOLOGISCHE INTERVENTIES NA RISICO REDUCERENDE 
EIERSTOKVERWIJDERING.
Vrouwen die kiezen voor preventieve eierstokverwijdering komen vroegtijdig in de 
overgang omdat de hormoonproductie van de eierstokken abrupt wegvalt. Deze 
vrouwen hebben vaak last van klachten zoals opvliegers, nachtelijk zweten en vaginale 
droogheid. De ernst en duur van deze klachten worden vaak onderschat. Voor sommige 
vrouwen is het een optie om een hormoonbehandeling te krijgen om de ontbrekende 
hormonen weer aan te vullen. Voor vrouwen die borstkanker hebben gehad is dit 
geen optie, omdat hierdoor de kans om opnieuw borstkanker te krijgen stijgt. Omdat 
borstkanker vaker voorkomt bij vrouwen met een BRCA1/2 mutatie is het van belang om 
te zoeken naar alternatieve behandelingen voor de overgangsklachten na preventieve 
eierstokverwijdering. 
In hoofdstuk 5 werden de ernst en duur van overgangsklachten gemeten in vrouwen die 
na een preventieve eierstokverwijdering in de overgang kwamen. Na gemiddeld 8 jaar 
had 70% van de vrouwen nog matige tot ernstige overgangsklachten. De klachten zoals 
pijn tijdens het plassen, een droge en/of jeukerige vagina en pijn tijdens seks kwamen 
het meeste voor. Ook werden psychologische klachten vaak genoemd (bijvoorbeeld 
depressiviteit, prikkelbaarheid, angstigheid). Vrouwen die in hun leven al eens borstkanker 
hadden gehad hadden meer overgangsklachten.
Zoals eerder gezegd, is het van belang om te zoeken naar alternatieve behandelingen 
voor de overgangsklachten na preventieve eierstokverwijdering. Een van de mogelijke 
alternatieven is een psychologische behandeling zoals (cognitieve)gedragstherapie of 
mindfulness training. Psychologische behandeling zou op twee manieren kunnen werken. 
Allereerst, zou het kunnen helpen door vrouwen technieken te leren waardoor zij beter 
om kunnen gaan met de klachten. Ten tweede kunnen psychologische behandelingen 
ook helpen stress te verlagen. Stress kan een trigger voor een opvlieger zijn en door stress 
te verlagen zou het kunnen dat een vrouw minder opvliegers heeft.
In hoofdstuk 6 is op systematische wijze een overzicht gemaakt van al het eerder verrichte 
onderzoek naar de effectiviteit van psychologische behandelingen van overgangsklachten. 
Nadat de bevindingen van deze publicaties gecombineerd werden kon overkoepelend 
de conclusie worden getrokken dat psychologische behandelingen effectief waren in het 
verminderen van de ervaren last van opvliegers en andere overgangsklachten. Het aantal 
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opvliegers leek niet te verminderen onder invloed van psychologische behandelingen. 
Opvallend was dat er nauwelijks publicaties waren over het effect van psychologische 
behandelingen op seksuele problemen aangezien dit probleem wel vaak genoemd wordt 
door vrouwen na preventieve eierstokverwijdering. 
In hoofdstuk 7 wordt er een nieuwe studie beschreven die het effect van een stress-
verlagende mindfulness training op overgangsklachten onderzocht. Een verbetering 
ten opzichte van meeste eerdere studies is dat in deze studie ook het lange termijn 
effect onderzocht werd en daarnaast ook het effect op seksuele klachten in kaart werd 
gebracht. Uit deze studie bleek dat mindfulness training inderdaad de ervaren last 
van overgangsklachten verbeterde en dit effect was na een jaar nog steeds aanwezig. 
De seksuele klachten verbeteren niet onder invloed van de mindfulness training. De 
uitkomsten van dit onderzoek kunnen een eerste stap zijn in het vaker gebruik maken 
van psychologische behandelingen bij vrouwen na een preventieve eierstokverwijdering. 
Echter, er moet wel verder onderzoek verricht worden naar een veilige en effectieve 
behandeling van seksuele klachten na preventieve eierstokverwijdering.
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Het moment om een dankwoord te schrijven is eindelijk aangebroken en ik wil me hierin 
graag richten aan iedereen die me in deze reis geholpen hebben.
Allereerst ben ik mijn promotoren prof. Mourits en prof. de Bock en copromotor dr. 
Oosterwijk erg dankbaar zonder wiens begeleiding en toewijding dit proefschrift niet 
voor u zou hebben gelegen. Beste Marian, jouw enthousiasme en energie hebben me 
vaak het vertrouwen gegeven om door te blijven zetten; door jou zat het glas altijd halfvol, 
wat de omstandigheden ook waren. Beste Truuske, jij bent degene geweest die mij heeft 
geïntroduceerd in de wereld van het medisch-wetenschappelijk onderzoek als bachelor 
student. Dat is ondertussen al bijna 9 jaar geleden en gedurende deze jaren heb ik altijd 
kunnen bouwen op je soms strenge, maar altijd eerlijke reflecties op mijn werk. Beste Jan, 
je hebt talloze keren tijd vrijgemaakt om nauwkeurig op mijn stukken in te gaan. Ik vind je 
een inspirerend voorbeeld van hoe empathie en zachtmoedigheid hand in hand kunnen 
gaan met een scherpe kritische blik en de nodige spitsvondigheid. Ik waardeer dat jullie 
mij nooit de mogelijkheid uit handen hebben genomen om zelf te groeien. Ik hoop jullie 
in mijn toekomstige onderneming, in het UMCG of elders, nog regelmatig te treffen.
Vervolgens wil ik graag prof. Ranchor, prof. Aaronson en prof. Hoogerbrugge hartelijk 
bedanken voor het lezen en beoordelen van dit proefschrift.
Daarna zou ik graag stilstaan bij de mensen die bijgedragen hebben aan de totstandkoming 
van de PURSUE studie. Allereerst gaat mijn grote dank gaat uit naar alle vrouwen die 
hebben willen deelnemen aan het onderzoek en daarmee een belangrijke bijdrage 
hebben geleverd aan dit proefschrift. Ook wil ik dr. Schroevers bedanken voor haar 
onmisbare inzicht en kennis in het doen van onderzoek naar mindfulness gebaseerde 
interventies. Beste Maya, in de laatste helft van mijn promotie onderzoek heb ik je 
leren kennen als een gedreven onderzoeker die gericht is op het behalen van een hoge 
methodologische kwaliteit. Dit is de PURSUE studie en daarmee mijn proefschrift duidelijk 
ten goede gekomen. Daarnaast heb ik ook op een persoonlijk niveau het contact met jou 
als erg aanmoedigend ervaren. Verder heb ik het genoegen gehad om Greetje Kuiken, 
Gillian Kreugel, Fokje Westerling en José Keurentjes te leren kennen. Jullie concrete 
bijdrage, maar ook de gesprekken die ik met jullie over de PURSUE studie heb gehad zijn 
voor mij onmisbaar geweest; hartelijk dank hiervoor. Als laatste wil ik de C.W. de Boer 
stichting bedanken voor het financieel mogelijk maken deze studie uit te voeren.
Dit proefschrift is geschreven tijdens een MD/PhD traject, waarvoor ik het Junior 
Scientific Masterclass (JSM) erkentelijk ben. De JSM maakt het in Groningen voor 
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geneeskundestudenten mogelijk om naast hun co-schappen ook een PhD te behalen. In 
het bijzonder ben ik Jans en Joke dankbaar voor hun inzichtgevende suggesties.
Ook wil ik Annette Claus van de afdeling klinische genetica bedanken voor haar hulp bij 
het vinden en duiden van vele genetische dossiers die toentertijd grotendeels nog op 
papier werden opgeslagen. 
Bij de start van mijn promotietraject ben ik een aantal mede promovendi tegengekomen 
die mij geholpen hebben wegwijs te worden in de praktische zaken rondom het doen van 
onderzoek. Welmoed, Janet en Ingrid, bedankt voor jullie hulp en inzichten. Met jullie 
hulp kwam ik soepel uit de startblokken. 
Een deel van het onderzoek is uitgevoerd met hulp van studentonderzoekers. Anniek en 
Nienke, bedankt dat jullie je stage wetenschap bij mij hebben uitgevoerd. Ik vond het erg 
leuk jullie te begeleiden en vind het daardoor des temeer ontzettend leuk dat jullie nu beide 
zelf ook bezig zijn met jullie promotietraject. Anniek, naast het inhoudelijke onderzoekswerk 
heb ik ook veel genoten van onze vele theologische discussies, gezellige lunchafspraken 
en de mogelijkheid om nog eenmaal een van je begeleiders te zijn tijdens je co-schap 
psychiatrie. Beste Nienke, ik heb je leren kennen tijdens mijn co-schappen in Hardenberg 
waar we snel goede vrienden zijn geworden. Ik was blij dat je je stage wetenschap bij mij 
wilde doen en ben trots je als paranimf jaren later aan mijn zijde te mogen hebben.
Ik zou graag alle coauteurs willen bedanken voor hun bijdrage aan het schrijven van de 
artikelen die onderdeel zijn van dit proefschrift. Dit zijn Yassir Eltahir, Jaap de Vries, 
Jan Jaspers, Hanne Meijers-Heijboer, Christi van Asperen, Ingenborg Zeijlmans van 
Emmichoven, Lidewij Henneman, Daniëlle Timmermans, Henriëtte Arts, Aisha Sie en 
Harry Hollema. 
Gedurende het MD/PhD traject heb ik gekozen me te specialiseren tot psychiater waar 
ik een aantal mensen voor wil bedanken. Ik wil Jitske Teeuwisse, begeleider van mijn 
eerste co-schap psychiatrie te Hardenberg, hartelijk bedanken. De eerste ochtend dat 
ik meeliep met jouw poli spreekuur was ik meteen helemaal verkocht. In het bijzonder 
vond ik onze samenwerking in het geven van een mindfulness training in Hardenberg een 
onmisbare ervaring. Mijn semi-arts stage volgde ik onder begeleiding van Wim Veling. 
Beste Wim, bedankt dat je me niet alleen bij je kliniek hebt betrokken, maar ook bij je 
onderzoek. Ik kijk met veel plezier de komende onderzoeksprojecten tegemoet. Een van 
deze onderzoeksprojecten is in samenwerking met Vera Brink, een kersverse MD/PhD 
student. Beste Vera, ik haal er ontzettend veel plezier uit om de zaken waar ik niet al te 
lang geleden mee bezig was nu aan jou door te geven. Ik zie ernaar uit je te begeleiden in 
je promotietraject. In april 2018 ben ik gestart met de opleiding tot psychiater in het UCP. 
Ik zou graag Iris Jonker, Janna Gol, Petra van Paasen, het team van de poli soma en 
psyche, Willeke van Zelst en Wim Winthorst bedanken voor het warme welkom aan de 
start van mijn opleiding.
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Dankwoord
Ik zou nu graag enkele goede vrienden bedanken. Beste keizer van China, allerliefste 
Paulien, ik ken je al sinds voor het internet en kan mijn leven niet voorstellen zonder een 
dubbel dikke dosis van jouw gevatte humor. Ik ben blij dat als mijn dromen te bescheiden 
worden jij me altijd weer aanslingert om naar de sterren te reiken. Lieve Marlies, ik ben 
blij dat ook nu we niet meer als bestuur aan elkaar verbonden zijn je er altijd bent om met 
een glas wijn te praten over de zin en onzin van het leven en vele polibrief-achterstanden 
weg te werken. Albert en Annegeerte, mes amis, met jullie heb ik de nodige momenten 
kunnen nemen om echt even helemaal weg te zijn van werk en verplichtingen. Ik heb 
enorm genoten van onze gezamenlijke vakantie, zoevend met onze cabrio door het 
Franse landschap. Lieve Kitty, je bent mijn studiemaatje en vriendin sinds dag één 
van de opleiding. Ik ben blij dat ik de laatste jaren vele mooie gebeurtenissen zoals de 
geboorte van jullie zoon met je heb mogen vieren en zo ook deze dag. Beste Liselotte, na 
onze klinische trainingen zijn we elkaar niet meer uit het oog verloren. We vonden vaak 
herkenning in de uitdagingen in elkaars promotietraject welke we nu beide succesvol 
afronden. Als laatste dank aan mijn vrienden Carmen, Aljan, Dirk-Jan, Helmich, Thijs, 
Laurens, Hylke, Annemarte, Hugo, Tom, Naomi, Daan, Job, Melanie en de rest van de 
Sinterkerstgroep.
Naast vrienden heb ik veel steun gehad aan mijn familie. Beste Roelof en Judith, 
dankjulliewel dat jullie tot twee keer toe mijn mooie momenten mooier hebben gemaakt. 
Eenmaal door mij en Dirk te trouwen en nu nogmaals door de kaft en stijl van mijn 
proefschrift te ontwerpen. Lieve Harald, Wendela, Nicolette en Ewan, onze band is 
misschien niet traditioneel, maar toch waardeer ik jullie zeer. Dank dat jullie deze dag met 
mij willen vieren. Dat er nog maar veel mooie momenten mogen volgen. Lieve Wouter, in 
onze bijzondere familie kwam ik als jongvolwassene Wouter ineens weer op het spoor en 
ontdekte ik hoe erg ik een natuurlijke klik bij je voelde. Het is zo bitter en zoet, omdat ik 
weet dat ik binnenkort weer zonder je verder moet. Ik wens jou, Lisanne en de kinderen 
veel sterkte de komende maanden. Papmam, jullie zijn voor mij het begin van het begin. 
Pappa, jij hebt mijn nieuwsgierigheid aangewakkerd. Ik weet nog wel de encyclopedieën 
en informatie lijnen die je raadpleegde op zoek naar mijn vurig gewenste antwoorden. 
Mamma, jij hebt mij gebeeldhouwd. Waar ik onstuimig kon zijn, hielp jij mij om mijn 
denken te verfijnen en niet met oppervlakkigheid genoegen te nemen.
Lieve Dirk, het is niet mogelijk om mijn dankbaarheid in een paar zinnen te vatten. Je 
hebt me onvoorwaardelijk gesteund en het daarmee voor mij mogelijk gemaakt om mijn 
passie na te jagen. Het feit dat jij ondertussen, ondanks alle chaos die ik veroorzaak, net zo 
hard hebt geklust aan jouw carrière (en nu ook promotie onderzoek!) inspireert me elke 
dag weer. Ik bewonder je om je onbaatzuchtigheid, stabiliteit en oprechtheid. Ik proost op 
nog vele jaren waarin wij samen de wereld mogen bestormen, lieve liefste.
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Catheleine van Driel is geboren op 1 maart 1989 te Zwolle. Zij heeft het tweetalig 
atheneum gedaan op de van der Capellen scholengemeenschap te Zwolle waar ze in 
2007 haar diploma behaalde.
Hierop aansluitend startte ze haar studie Geneeskunde aan de Rijksuniversiteit Groningen 
waar ze diverse commissies deed, waaronder een bestuursjaar als voorzitter van de 
internationale geneeskunde studenten vereniging IFMSA-Groningen. Een proefproject 
van de junior scientific masterclass deed Catheleine onder de supervisie van prof. dr. G.H. 
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Naast het promotieonderzoek beschreven in deze thesis, deed Catheleine in deze periode 
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